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SUMMARY 
Membrane transport proteins carry nutrients and other compounds into the cell and 
eliminate toxic metabolites and xenobiotic agents in order to maintain cellular homeostasis. 
These transporters are designed to facilitate the transport of bile acids, peptides, amino 
acids, fatty acids, and other compounds. Protein malfunction or genetic polymorphisms can 
influence the transport activity of these proteins. 
 
The apical sodium-dependent bile acid transporter (ASBT; gene symbol SLC10A2) is 
expressed abundantly in the ileum and mediates bile acid (BA) absorption across apical 
membranes of ileocytes. Caudal-type homeobox proteins CDX1 and CDX2 are 
transcription factors that regulate genes involved in intestinal epithelial differentiation and 
proliferation. The first aim of my research was to study the aberrant expression of both 
ASBT and CDXs in Barrett’s esophagus (BE), and whether expression of the ASBT gene 
was regulated by CDXs. Short interfering RNA-mediated knockdown of CDXs resulted in 
reduced ASBT mRNA expression in intestinal cells. CDXs strongly induced the activity of 
the ASBT promoter in reporter assays in esophageal and intestinal cells. Nine CDX binding 
sites were predicted in silico within the ASBT promoter, and binding of CDXs to six of 
them was verified in vitro and within living cells by electrophoretic mobility shift assays 
and chromatin immunoprecipitation assays, respectively. RNAs were extracted from 
esophageal biopsies from 20 BE patients, and analyzed by real-time PCR. Correlation with 
ASBT mRNA expression was found for CDX1, CDX2, and hepatocyte nuclear factor-1α 
(HNF-1α) mRNA in BE biopsies. The human ASBT promoter was activated 
transcriptionally by CDX1 and CDX2. The results provide a possible explanation for the 
reported observation that ASBT is aberrantly expressed in esophageal metaplasia that also 
expresses CDX transcription factors. I have also presented preliminary results on organic 
solute transporter (OST) α/β promoter regulation by CDXs, whereby silencing CDX1 and 
CDX2 expression reduced endogenous OSTα/β  at the mRNA level, and overexpression of 
CDXs elevated OSTα promoter activity. 
 
The role of CDX factors in intestinal differentiation and their aberrant expression levels in 
intestinal metaplasia are well established. However, relatively little is known about the 
exact molecular mechanisms by which CDXs exert their function as transcriptional 
  
 
activators or repressors. The second aim of my research was to identify protein interacting 
partners of CDXs that may mediate or modulate their transcriptional activity. To this end, I 
constructed a phage cDNA expression library using poly(A) RNA derived from the human 
small intestine and colon. Characterization of the library revealed it to be of high quality. 
The unamplified library contained 4.5×106
 
independent clones, with 99.6% of the phage 
vectors containing an insert. I performed primary far western screening (1.7×106
 
clones 
screened per CDX protein) and secondary protein interaction screening using 35S-
radiolabelled in vitro translated CDX1 and CDX2 proteins. The screening identified 
several clones encoding potential novel molecules that interact with CDX. One promising 
cDNA clone encoded the BRD1 protein, which contains a bromodomain that is frequently 
present in transcriptional coactivator proteins. I am currently at the validation phase to 
confirm that the positive clones from the far western screening encode true interacting 
partners. 
 
  
 
 
ZUSAMMENFASSUNG 
Membrantransportproteine transportieren Nährstoffe in, sowie toxische Abbauprodukte 
und Xenobiotika aus der Zelle hinaus. Wichtige Substrate von Transportproteinen 
umfassen wichtige Verbindungen wie z.B. Peptide, Aminosäuren oder Fettsäuren. 
Proteinfehlfunktionen oder genetische Polymorphismen können die Transportaktivität 
dieser Transportproteine beeinflussen. 
 
Der Apical sodium-dependent bile acid transporter (ASBT) wird vor allem im Ileum 
exprimiert und ist massgeblich an der Gallensalzaufnahme über die apikale Membran 
beteiligt. Caudal-type homeobox proteins CDX1 and CDX2 sind Transkriptionsfaktoren, 
welche Gene regulieren, die eine Rolle in der Differenzierung und Proliferation von 
intestinalen Epithelzellen spielen. Das erste Ziel meiner Forschungsarbeit war es, zu 
untersuchen, ob Abweichungen der ASBT- und CDX- Expression in Barrett-Ösophagus-
Gewebe (BE-Gewebe) nachzuweisen sind und zu ergründen, ob die Expression des ASBT-
Genes von CDX reguliert wird. Mittels si-RNA-knockdown-Experimenten in intestinalen 
Zelllinien, welche die CDX-Expression herabsetzten, konnte gezeigt werden, dass die 
ASBT-Expression, quantifiziert mittels ASBT-mRNA-Konzentrationsbestimmung, 
signifikant herabgesetzt wurde. In Gen-Reporter-Assays, durchgeführt in ösophagialen und 
intestinalen Zelllinien, konnte gezeigt werden, dass CDXs die Fähigkeit haben, den ASBT-
Promoter stark zu induzieren. Neun CDX-Bindungsstellen wurden durch in-silico-Analyse 
in der ASBT-Promotorregion identifiziert. Die Bindung von CDXs an sechs der neun 
vorhergesagten Bindungsstellen konnte in vitro mittels  Elektromobilität-Shift-Analyse 
(EMSA) und in intakten Zellen mittels Chromatin-Immunopräzipitation bestätigt werden. 
Die aus Biopsien von 20 BE-Patienten  extrahierte RNA wurde mittels Realtime-PCR 
analysiert. Hier konnte eine Korrelation zwischen der Expression von ASBT und CDX1, 
CDX2 sowie dem hepatocyte nuclear factor-1α (HNF1α)nachgewiesen werden. Der 
Humane ASBT-Promoter wird auf Transkriptionsebene durch CDX1 und CDX2 aktiviert. 
Dieses Resultat könnte eine mögliche Erklärung für die zuvor beobachtete aberrante 
Expression von ASBT in metaplastischem Gewebe des Ösophagus sein, welches ebenfalls 
CDX-Transkriptionsfaktoren exprimiert.  
 
  
 
Desweiteren präsentiert die vorliegende Arbeit Daten zur Regulation der Transportproteine 
organic solute transporter α und β (OSTα/β)  durch die Transkriptionsfaktoren CDX1 und 
CDX2. Ich konnte zeigen, dass das Ausschalten der Expression von CDX1 und CDX2 zu 
einer Reduzierung von endogener OSTα/β−mRNA führt und eine Überexpression von 
CDX1 und CDX2 eine erhöhte Expression von OSTα-mRNA zur Folge hat.  
 
Die Rolle, die CDX-Transkriptionsfaktoren in der intestinalen Differenzierung spielen 
sowie und ihre aberrante Expression in intestinalem metaplastischem Gewebe sind bereits 
gut erforscht. Jedoch war bisher wenig bekannt darüber, über welche exakten molekularen 
Mechanismen CDXs ihre aktivierende oder reprimierende Wirkung auf die Transkription 
von Genen ausüben. Das zweite Ziel meiner Forschungsarbeit war es daher, die mit CDX 
interagierenden Proteine, welche vermittelnd oder modulierend auf die 
Transkriptionsaktivität wirken, näher zu untersuchen.  
 
Zu diesem Zweck habe ich eine Phagen-cDNA-Expressionsbibliothek mit Hilfe von 
poly(a)RNA, gewonnen aus humanen Dünndarm- und Dickdarm-Zellen, erstellt. Die 
Charakterisierung der Bibliothek bestätigte die hohe Qualität derselben. Die 
nichtamplifizierte Bibliothek enthielt 4.5×106
 
 unabhängige Klone, wobei 99.6% der 
Phagenvektoren ein Insert trugen. Ich habe ein primäres Screening (1.7×106
 
Klone per 
CDX-Protein) und ein sekundäres Far-Western-Protein-Interaktionsscreening mit in vitro 
translatiertem, 35S-gelabeltem, CDX1 und CDX2 durchgeführt. Das Screening führte zur 
Identifizierung mehrerer Klone, die potenziell für noch nicht bekannte Interaktionspartner 
für CDX-Proteine kodieren. Einer der vielversprechenden cDNA-Klone kodiert für das 
BRD1 Protein, welches ein Bromo-Domäne enthält, eine Proteinstruktur, die häufig in 
Molekülen mit Ko-Aktivatorfunktion zu finden ist. Ich evaluiere nun derzeit, inwieweit die 
positiven Klone des Far–Western-Screenings für wahre Interaktionspartner von CDX-
Proteinen kodieren. 
  
 
 
LIST OF ABBREVIATIONS    
 
ABC transporter ATP-binding cassette transporter 
ASBT       apical sodium-dependent bile acid transporter 
BE      Barrett’s esophagus 
BSEP      bile salt export pump 
C/EBP   CCAAT enhancer-binding protein 
CA    cholic acid 
CAD   coronary artery disease 
CBDL   common bile duct ligation 
CDCA   chenodeoxycholic acid 
COX2   cyclo-oxygenase 2 
CREB    cAMP response element-binding 
DCA   deoxycholic acid 
EAC   esophageal adenocarcinoma 
EGCG   epigallocatechin-3-gallate  
EGFR    epidermal growth factor receptor 
FXR      farnesoid X receptor 
GEJ   gastroesophageal junction 
GCA   glycocholic acid 
HGD   high grade dysplasia 
HNF      hepatocyte nuclear factor 
IBABP  ileal bile acid-binding protein 
IBD   inflammatory bowel disease 
IHC    immunohistochemical 
IL      interleukin 
IM   intestinal metaplasia 
IR-1    inverted repeat-1 
JNK     Jun N-terminal kinase 
LCA   lithocholic acid 
LGD   low grade dysplasia 
LPS    lipopolysaccharide 
  
 
LRH     liver receptor homologue 
MAPK   mitogen-activated protein kinase  
MRP     multidrug resistance protein 
MβCD   methyl-β-cyclodextrin  
NTCP   Na+-taurocholate cotransporting polypeptide 
OATP    organic anion transporting polypeptide 
OST    organic solute transporter 
PBC   primary biliary cirrhosis 
PEPT1   peptide transporter 1  
PFIC     progressive familial intrahepatic cholestasis 
PKC    protein kinase C 
PMA   phorbol-12-myristate-13-acetate 
PXR     pregnane X receptor 
RAR/RXR     retinoic acid receptor/retinoid X receptor 
SCMT1  sodium-coupled monocarboxylate transporter 1  
SHP     small heterodimer partner 
SREBPs   sterol regulatory element-binding proteins  
TGFα   transforming growth factor-α 
TNFα     tumour necrosis factor-α    
UDCA   ursodeoxycholic acid 
VDR   vitamin D receptor 
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1 INTRODUCTION 
 
1.1 Bile acid (BA) synthesis 
BAs are synthesized as a result of cholesterol metabolism in the liver, and 
approximately 50% of cholesterol is eliminated by its conversion into BAs. BAs 
function as physiological detergents to facilitate the intestinal absorption of dietary 
fats and fat-soluble vitamins. BAs are synthesized via two pathways. Ninety percent 
of the BAs are made via the classic pathway that takes place in the liver. Here, 
cholesterol is first converted to 7α-hydroxycholesterol via the cholesterol-7α-
hydroxylase (CYP7A1) - the first and rate-limiting enzyme (Fig. 1.1). The 
alternative/acidic bile acid synthesis, ie. the remaining 10 %, is primarily catalysed 
by the sterol 27-hydroxylase (CYP27A1) [1]. The latter pathway occurs when the 
classic synthesis pathway is blocked by low CYP7A1 activity [2]. The synthesis of 
BAs from cholesterol consists of 15 enzymatic steps [3].   
 
     
  
 
Fig. 1.1 From cholesterol to BAs.  Conversion of cholesterol to BAs is initiated with the 
modification of sterol ring and is followed by side chain cleavage. Human primary BAs 
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formed from the cholesterol in the liver are cholic acid (CA) and chenodeoxycholic acid 
(CDCA). Secondary BAs are formed in the colon by bacteria, and include deoxycholic acid 
(DCA), lithocholic acid (LCA), and ursodeoxycholic acid (UDCA). Taken from Khurana et 
al [4]. 
1.2 Enterohepatic circulation of BAs 
Healthy human adults have approximately 3-4 g of BAs, which circulate 6-8 
times/day between the liver and intestine. During the fasting stage, BAs are stored in 
the gallbladder, from which they are released into the intestine upon food intake, in 
order to aid digestion of lipids and fats into micelles. Approximately 95 % of BAs 
are reabsorbed actively by the apical sodium-dependent bile acid transporter (ASBT; 
SLC10A2 gene) in the terminal ileum via active sodium-dependent uptake. Within 
the enterocytes, BAs bind to the cytoplasmic transporter protein ileal bile acid-
binding protein (IBABP), and are exported into the portal venous blood via the 
heterodimeric membrane transporter organic solute transporter (OST) -α and OSTβ 
on the basolateral membrane [5, 6]. In the small intestine and colon, the primary BAs 
are deconjugated after exposure to the gut flora. In the liver, BAs are taken up mainly 
by the Na+-dependent taurocholate-cotransporting polypeptide (NTCP; SLC10A1) on 
the sinusoidal hepatocyte membrane [7], whereas organic anion-transporting 
polypeptides (OATPs, SLCOs) are responsible for the minor sodium-independent 
bile acid uptake into hepatocytes. At the canalicular membranes of hepatocytes, BAs 
are exported to the bile via the ATP-dependent bile salt export pump (BSEP; 
ABCB11). Also present on the canalicular side, are other ATP-binding cassette 
(ABC) transporters, namely the multidrug resistance-associated protein-2 (MRP2; 
ABCC2). The flow of BAs from the small intestine via the liver to the gallbladder 
completes their enterohepatic circulation (Fig 1.2). This is an efficient and tightly 
regulated uptake and efflux process: less than 5 % of the intestinal BAs escape from 
reabsorption into the systemic circulation, and are released into the faeces.  
INTRODUCTION  12   
 
 
 
 
 
Fig. 1.2 Overview of the enterohepatic circulation and systemic circulation. BAs 
undergo efflux into the portal blood via the heterodimeric OSTα/β at the basolateral 
membrane of enterocytes. Together with the basolateral BA uptake system NTCP at the 
sinusoidal membrane of hepatocytes and BSEP at the liver canalicular membrane. ASBT and 
OSTα/β maintain efficient enterohepatic BA circulation and cholesterol homeostasis [8, 9]. 
BAs that are not absorbed in the ileum are reabsorbed at the colon. Spilled BAs from 
hepatocytes are reabsorbed by the renal proximal tubule cells, returned back to liver, and 
resecreted into bile. Taken from Dawson et al [10]. 
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1.3 Regulation of BA transport 
1.3.1 Nuclear receptors for BAs 
The expression levels of membrane transporters alter under different physiological 
and pathological conditions. In addition to their detergent function, BAs are 
signalling molecules. The farnesoid X receptor (FXR, NR1H4) was the first nuclear 
receptor for BAs identified, and is strongly activated by the BA ligand CDCA, as 
well as the secondary BAs LCA and DCA [8, 11, 12]. FXR is expressed in the liver, 
kidney, intestine, and adrenal gland. In most cases, FXR forms heterodimers with 
another nuclear receptor, the retinoid X receptor-α (RXRα; NR2B1) in order to bind 
to FXR response elements and to transactivate target genes [13]. The FXR:RXRα 
heterodimer can induce the expression of a repressor nuclear receptor, the small 
heterodimer partner (SHP; NR0B2), which consequently represses CYP7A1 promoter 
activity, thereby inhibiting BA synthesis. This forms a negative feedback loop 
existing to prevents cells from becoming overloaded with BAs (reviewed in [14]).  
 
BA transporter genes are under strict transcriptional regulation. FXR plays an 
important role in hepatic BA homeostasis. In wild-type mice, upon feeding with 1 % 
CA, Ntcp, and Cyp7a1 expression are downregulated, while Bsep expression is 
upregulated [15]. In Fxr knockout mice, no change in the Ntcp and Bsep expression 
is observed in the liver. Under cholestatic conditions, where there is significant 
accumulation of BA in the hepatocytes, FXR acts by inducing BSEP expression in 
order to increase bile efflux from hepatocytes, as well as inhibiting BA uptake via 
NTCP [16]. Expression of the BA efflux system OSTα/β is also upregulated via the 
bile acid receptor FXR in the human liver and intestine [17, 18]. 
Vitamin D receptor (VDR; NR1I1), also known as the calcitriol receptor, is activated 
by its natural ligand, 1,25-dihydroxyvitamin D3 [1,25(OH)D3], as well as by the 
secondary BA LCA [19, 20]. Similarly to FXR, upon ligand binding, VDR 
heterodimerizes with RXRα in order to bind downstream target gene promoters, such 
as the CYP3A promoter [20].  
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Pregnane X receptor (PXR; NR1I2) was first cloned from mice and described in 1998 
[21], and is activated by naturally occurring steroids. The BAs LCA and 3-keto-LCA 
are also potent activators of PXR. Studies in Pxr-null mice have demonstrated that, 
Pxr has a protective role against liver damage, because activation of Pxr by LCA 
represses Cyp7a1 and thus reduces BA production [22]. 
1.4 BA signalling via other pathways 
Increasing evidence suggests that BAs also function as signalling molecules in 
further physiological processes, in addition to their well-established roles in lipid 
absorption and cholesterol homeostasis. BAs interact with multiple signalling 
pathways beyond nuclear receptors, and can regulate triglyceride, cholesterol, energy, 
and glucose homeostasis [23]. BAs can activate the Jun N-terminal kinase (JNK)/c-
Jun cascade in rat primary hepatocytes and consequently downregulate Cyp7a1 and 
BA synthesis [24]. DCA has also been shown to activate the extracellular signal-
regulated kinase (ERK) pathway, as well as CCAAT-enhancer-binding proteins 
(C/EBPs), the cAMP response element-binding protein (CREB), and c-Jun signalling, 
as hepatocyte-protective mechanisms [25].  
 
In addition to BA-specific nuclear receptors described above, BAs have also been 
shown to interact directly with the membrane-type rhodopsin-like G-protein-coupled 
BA receptor (GPCR) TGR5 (also known as M-BAR) [26]. TGR5 is expressed in 
brown adipose tissue, spleen, macrophages, lung, fetal liver, colon, and ileum, and it 
plays a role in macrophage function in BA-induced immune responses [27]. The 
absence of Tgr5 in an animal model has revealed its role in intestinal homeostasis via 
regulation of intestinal permeability [28]. 
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1.5 ASBT 
1.5.1 General aspects 
The gene encoding the ASBT (gene symbol SLC10A2) is located on the human 
chromosomal position 13q33 [29]. It was first cloned from a hamster intestinal 
cDNA library [30]. This was followed by cloning of the human [31], rat [32], rabbit 
[33], and mouse [34] ASBT/Asbt homologues. The ASBT gene encodes a 48 kDa 
transmembrane protein expressed in the terminal ileum, biliary tract, and renal 
proximal tubule cells. Structural information of human ASBT membrane topology is 
not clear: membrane insertion scanning has predicted a nine transmembrane model 
[35], whereas using dual label epitope insertion scanning mutagenesis has a predicted 
seven transmembrane topology [36]. Crystal structure of the bacterial Neisseria 
meningitidis homologue of ASBT consists of 10 transmembranes (Fig. 1.3) [37]. 
BAs are transported into the cell at a stoichiometry of two sodium ions per one BA 
molecule [38]. At the apical membranes of ileal enterocytes, ASBT is the chief 
mediator of active sodium-dependent intestinal BA absorption [39] and it has a 
higher affinity for unconjugated BAs (CA, DCA, CDCA, and UDCA) than 
conjugated BAs or taurocholate [40].  
 
Fig. 1.3 Crystal structure of the bacterial (Neisseria meningitidis) homologue of ASBT. 
A ribbon representation of an ASBT homologue consists of 10 transmembranes, with red 
colour at the N-terminus and blue colour at the C-terminus. Pink spheres depict the sodium 
position 1 and 2, and the position of taurocholate is indicated in dark pink. Taken from Hu et 
al [37]. 
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1.5.2 Regulation of ASBT by BA 
In Asbt-/- mice [41], the BA circulation is disrupted, and Cyp7a1 expression is 
increased 2.7-fold in male mice and 5.2-fold in female mice. The regulation of ASBT 
expression by BAs has remained somewhat controversial, given that the experiments 
have been conducted in different species and cell lines. Chen et al have shown that 
mice fed with BAs exhibit decreased Asbt expression at the protein and mRNA level, 
and have proposed that this negative feedback mechanism is mediated by Fxr via 
short heterodimer partner (Shp)-dependent repression of the Asbt promoter [42]. In 
rabbits, DCA feeding represses Asbt expression via elevating Shp levels in the ileum 
[43].  
1.5.3 Non-BA-dependent transcriptional and post-transcriptional regulatory 
mechanisms of ASBT expression and function 
Prior studies have shown that ASBT gene expression is controlled at the 
transcriptional level in a complex manner: Known transcriptional regulators of the 
human ASBT promoter include the glucocorticoid receptor (GR) [44] and hepatocyte 
nuclear factor-1 α (HNF)-1α [45]. Consistent with the latter, Hnf-1α knockout mice 
show reduced Asbt mRNA and protein levels, implying that Hnf-1α is involved in 
maintaining the basal expression level of Asbt [46]. Other regulators of the 
ASBT/Asbt promoter include the peroxisome proliferator-activated receptor-α 
(PPARα) [45] and, in rats, VDR [47].  Both serum [48] and certain BAs [49] appear 
to elevate ASBT expression via activator protein-1 (AP)-1. In addition, cholesterol 
has been shown to modulate human ASBT expression in Caco-2 cells: the 
cholesterol derivative 25-hydroxycholesterol inhibits the ASBT expression at the 
mRNA and promoter level [50] via the transcription factors sterol regulatory 
element-binding protein (SREBP)-2 and HNF-1α [51]. However, this effect has been 
contradicted in further cholesterol-feeding animal models: no change of ASBT 
expression is observed in rats, whereas its expression is induced in rabbits [52]. 
Treatment with inflammatory cytokines interleukin (IL)-1β and tumour necrosis 
factor (TNF)-α significantly reduces human ASBT promoter activity, and this effect 
is mediated by the transcription factor c-Fos [53]. At the post-transcriptional level, 
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ASBT expression is reduced by cholesterol depletion with methyl-β-cyclodextrin 
(MβCD) treatment, significantly reducing its interaction with lipid rafts [54]. 
Treatment with phorbol-12-myristate-13-acetate (PMA) decreases the ASBT 
transport activity via the protein kinase C (PKC) pathway [55]. In a knockout mouse 
model, the transcription factor Gata4 regulates the jejunal-ileal gradient of Asbt 
expression, which provides a molecular mechanism for the tissue-specific expression 
of Asbt in the terminal ileum [56]. 
1.5.4 Pathophysiology 
Alterations in ASBT function or ASBT gene expression have been associated with 
intestinal diseases in humans: Mutations in the ASBT gene can lead to BA 
malabsorption [57], whereas reduced ileal ASBT protein [44] or mRNA [58] levels 
have been found in patients with inflammatory bowel disease (IBD).  
1.5.5 Genome-wide studies and genetic polymorphisms of ASBT 
Genome-wide association and single nucleotide polymorphism (SNPs) studies have 
been reported for ASBT [59]. A genetic variant allele of the ASBT, rs9514089, is 
presented as a risk factor for male non-obese gallstone carriers [60], although in a 
more recent study in 2011, the same allele showed no association in a smaller cohort 
[61]. Therefore future larger cohort studies are needed to confirm these findings. A 
systematic study of the association between coding SNPs and the taurocholate 
transport function of ASBT, has shown a significant impairment for 292G>A and 
431G>A, whereas a rare novel variant 790A>G leads to the near complete loss of 
transport activity in comparison with the wild type [62]. 
1.5.6 ASBT inhibitors as therapeutic options 
Therapeutic drugs have been developed to inhibit ASBT activity in an attempt to 
lower serum cholesterol level [63]. The ASBT inhibitor (264W94) has been 
proposed as a candidate for the therapy of type 2 diabetes mellitus [64]. In a 
randomized clinical trial, another ASBT inhibitor, A3309, has been shown to be 
effective for treatment of chronic idiopathic constipation [65]. A novel monoclonal 
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antibody has been synthesized to target ASBT specifically, leading to the conversion 
of more cholesterol into BAs, thus making it a promising agent for treatment of 
hypercholesterolemia [66]. Interestingly, (-)-epigallocatechin-3-gallate (EGCG), a 
component of green tea, has been shown to inhibit ASBT, by altering the association 
of ASBT with lipid rafts on the plasma membrane [67]. Determination of the crystal 
structure of the Neisseria meningitides bacterial homologue of human ASBT may 
further advance the design of more potent ASBT inhibitors [37]. However, potential 
drug-induced side effects of ASBT inhibitors have been reported: For example,  
increased free BA concentrations following ASBT inhibitor treatment may be a 
major cause for diarrhea, gallstone disease, and hypertrigyceridemia [68]. 
 
Lowering the blood cholesterol content, especially low density lipoprotein (LDL) 
which is known to be atherogenic, has been a target in reducing the risk for vascular 
atherosclerosis. Several studies have revealed the potential contribution of BAs to 
cardiovascular conditions. For example, when comparing the BA excretion levels in 
patients with coronary artery disease (CAD) and CAD-free patients, the former 
group had a lower amount of total BA. Therefore, the BA excretion level may act as 
a predictor for CAD [69]. Blocking ASBT-mediated bile acid uptake with specific 
inhibitors can reduce serum cholesterol level and prevent atherosclerosis in animal 
models, for example in rabbits [70], apoE (-/-) mice [71], and in guinea pigs [72].  
1.6 OSTα /β  
1.6.1 General aspects 
Whereas ASBT on the apical membrane of ileocytes is responsible for BA uptake, 
the protein(s) that transport BA across the basolateral membrane of ileocytes to the 
portal blood remained unknown until 2001, when Wang et al first cloned OSTα/β 
from the sea animal little skate (Leucoraja erinacea), by expression profiling of its 
liver cDNA library [73]. The human and mouse orthologues were subsequently 
cloned by the same group in 2003 [74].  The OSTα and OSTβ genes are located on 
different chromosomes, at positions 3q29 and 15q22, respectively. Their transport 
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activity of the heterodimer is sodium-independent, saturable, and unaffected by 
intracellular ATP depletion [5]. In the case of estrone 3-sulfate transport, human and 
mouse OSTs/Osts cannot mediate transport when expressed individually in Xenopus 
ooctyes, transport only occurs when both subunits are coexpressed on the membrane 
[74]. The OSTα/β heterodimer is responsible for BA efflux into the portal blood in 
the ileum and other tissues where ASBT is expressed; it also transports estrone 3-
sulfate, dehydroepiandrosterone 3-sulfate (DHEAS), digoxin, prostaglandin E2 [5], 
and steroids [75]. OSTs are predominantly found at the mRNA level in the human 
testes, colon, liver, small intestine, kidneys, ovaries, and adrenal glands. Human 
OSTs are highly expressed in liver, whereas mouse Osts are expressed at low levels 
in the liver [76]. In mice, Ostα has a protein size of 50 kDa, although minor protein 
species bands can also be observed at around 80 kDa - the predicted molecular 
weight is 37.8 kDa. The mouse Ostβ forms two protein species at 19 and 17 kDa, 
with a predicted molecular weight is at 14.7 kDa. The protein sizes of the human 
OSTα and OSTβ are 37 and 19 kDa respectively [77]. OSTα and OSTβ interact 
directly to form a heterodimer, which stabilizes the protein complex. When they are 
expressed separately, OSTs undergo rapid degradation. The main function of OSTβ 
is to act as a chaperone to move the OSTα protein from the endoplasmic reticulum to 
the plasma membrane [78]. A study in the Ost knockout mice, has provided in vivo 
evidence for the Ost function in BA circulation, and has emphasized the important 
role of OSTs/Osts in BA homeostasis [79]. For example, in these mice, the 
accumulated BAs in the intestine has been shown to upregulate FXR, which then 
increases the hormone Fgf15, leading to a decrease in hepatic BA synthesis. 
1.6.2 Transcriptional regulatory mechanisms of OSTα/β  
OSTα/β  are direct target genes of FXR. Human OSTα/OSTβ promoter-reporter 
constructs can be induced by BAs via the presence of FXR response elements, and 
consistent with this, treatment of ileal biopsies with CDCA leads to elevated OST 
mRNA levels [18]. In accordance, Ostα/β mRNA levels are induced in the intestine 
and liver upon Fxr agonist GW4064 treatment in wild type but not in the Fxr (-/-) 
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mice [80]. In mice, the Ostα/β genes are regulated positively by BA via Fxr response 
elements and negatively via response elements for the nuclear receptor liver receptor 
homologue-1 (Lrh1), a Shp target, located on the promoter regions of the two genes.  
This dual regulation by Fxr and Lrh-1 allows the Ost gene expression to be adjusted 
by BA via both positive and negative feedback [81]. Furthermore, the mouse Ostα/β 
promoters are regulated by the liver X receptor-α (Lxrα)/Rxrα heterodimer via 
inverted repeat-1 (IR)-1 elements in the promoter region, and in the case of the Ostα 
promoter, another nuclear receptor hepatocyte nuclear factor-4α (Hnf-4α) can further 
increase the effect [82]. It also appears that the OST/Ost promoters are regulated in 
an organ- and species-specific manner, because VDR/Vdr ligands reduce Ostα/β 
expression in rat jejunum, ileum, colon, and liver, but have no effect on OST 
expression in the human ileum and liver [83]. 
1.6.3 Pathophysiology  
In human cholestatic liver injury, the adjustment of BA transporter expression aims 
to protect the liver from excess and toxic BAs by restricting their uptake and 
inducing their efflux, in addition to the reducing bile acid synthesis [84]. The 
expression of OSTs is upregulated in human primary biliary cirrhosis (PBC), and 
similarly to the rodent counterparts upon common bile duct ligation (CBDL), this 
effect is FXR-dependent [17]. OST expression levels have been observed in non-
obese female gallstone carriers in comparison with healthy control subjects [85]. 
Furthermore, the expression levels of OSTs strongly correlate with those for the BA 
receptor FXR in the entire study group. 
1.7 Caudal-type homeobox-1 (CDX1) and -2 (CDX2) 
1.7.1 General aspects 
CDX1, CDX2, CDX3, and CDX4 are transcription factors of the homeodomain 
family, and homologues of the Drosophila melanogaster protein Caudal that is 
essential for the early anterior-posterior development and body patterning [86]. 
Homeodomains are structurally conserved protein domains of ~60 amino acids and 
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contain helix-turn-helix motifs that can mediate protein binding to DNA in a 
sequence-specific manner. Many homeodomain transcription factors regulate 
patterns of anterior-posterior development in animals, fungi, and plants [87].  
 
CDX1 and CDX2 were first identified and cloned by the Mallo group from genes 
differentially expressed between the colon carcinoma and adjacent normal mucosa. 
Human CDX1 shares 85 % homology with mouse Cdx1, and human CDX2 shares 
94 % homology with the mouse Cdx2 [88]. Despite the high level of amino acid 
identity (95 %) within their DNA-binding domains, the two CDX factors play at least 
partially distinct roles in the intestine: Cdx1-/- mice exhibit a shift in the body frame 
[89], and Cdx2+/- heterozygous mutant mice develop colonic tumours [90]. These 
two mouse models also show differential responses upon inflammatory challenge 
[91]. Complete Cdx2-null mice are embryonically lethal, as evidently are Cdx1/Cdx2 
double-null mice. In adult mammals, CDXs/Cdxs are expressed exclusively in the 
small and large intestine, playing important roles in the proliferation and 
differentiation of intestinal epithelial cells. However, their levels have been reported 
to be aberrantly elevated in esophageal metaplasia, such as BE, compared to the 
adjacent normal tissue [92, 93]. Similarly to the BA transporters, CDX2 expression 
has been reported to be decreased upon progression of esophageal metaplasia into 
high-grade adenocarcinoma [94, 95]. 
 
1.7.2 Transcriptional target genes of CDX1 and CDX2 
A number of CDX1 and CDX2 transcriptional target genes have been identified so 
far. These include marker genes for intestinal differentiation, such as sucrase 
isomaltase (SI) [96], goblet-cell-specific mucin 2 [97], cell adhesion differentiation 
marker cytokeratin 20 [98], desmocollin 2 [99], E-cadherin [100], lactase [101], and 
VDR [102].  Certain CDX target genes encode intestinal transporters, such as the 
peptide transporter 1 (PEPT1; SLC15A1) [103] and the sodium-coupled 
monocarboxylate transporter 1 (SCMT1; SLC5A8) [104]. The observation that 
CDX2 regulates the ABCB1 gene encoding the multidrug resistance protein 1 
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(MDR1) may have implications in gastrointestinal cancers [105]. Furthermore, it has 
been suggested that CDX1 and CDX2 can regulate their own expression in 
esophageal cell lines, via both auto- and crossregulation [106]. CDXs also regulate 
several intestine-specific genes, such as those encoding SI [96] and NADPH oxidase 
(NOX1) [107], via an evolutionarily conserved mechanism involving cooperation 
with HNF-1α and members of the GATA transcription factor family. Furthermore, 
CDX2 can synergize with HNF-1α, leading to activation of the gene encoding the 
brush-border enzyme lactase-phlorizin hydrolase (LPH) [108].  
 
1.7.3 Role of CDXs in gastric metaplasia/carcinogenesis 
Gastric cancer develops through the following stages: normal gastric 
mucosa>gastritis>gastric atrophy>gastric cancer. Normal stomach does not express 
either CDX1 or CDX2. CDX1 and CDX2 have been consistently detected in gastric 
intestinal metaplasia (IM) by immunohistochemical (IHC) staining and RNA 
analysis [109-111]. CDX2 is also closely associated with gastric carcinoma 
differentiation status [112]. Expression of the homeobox gene CDX2 precedes that of 
CDX1 during the progression of IM [112]. The above evidence suggests that CDX1 
and CDX2 are involved in the development of gastric IM, which is also highlighted 
in transgenic Cdx1 and Cdx2 mice. In Cdx2 transgenic mice, normal gastric mucosal 
cells are replaced by IM on day 37, and gastric mucosal cells are transformed into 
enterocytes, goblet cells, and enteroendocrine cells, indicating that Cdx2 is an 
important transcription factor in this conversion process [113]. Furthermore, 
endogenous Cdx1 expression is induced by Cdx2 in IM of the stomach [114]. In 
Cdx1 transgenic mice, normal gastric mucosa was replaced by all four intestinal 
epithelial lineages; in this case, also Paneth cells are found. Pseudopyloric gland 
metaplasia, induced in Cdx2 transgenic mice, is not observed in Cdx1 transgenic 
mice. Cdx1 mice also have thicker metaplastic mucosa than Cdx2 mice. Overall, 
these data suggest that Cdx1 and Cdx2 can independently transform the normal 
gastric epithelium into epithelium of intestinal characteristics, although to a different 
extent in terms of degree of differentiation, structure, and proliferation [115]. CDX2 
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serves as a sensitive marker for intestinal-type gastric carcinoma and CDX2-positive 
patients show a better prognosis than CDX2-negative patients [116].  
  
1.7.4 The role of CDXs in colon cancer 
The tumour suppressor role of Cdx2 was first suggested in a mouse model in which 
Cdx2-/- mice died at birth, and the Cdx2+/- mice developed intestinal polyps [90]. The 
reduction or complete loss of CDX1 and CDX2 has been found in human colorectal 
carcinoma tissues compared to adjacent normal tissues and colon cancer-derived cell 
lines [88], suggesting that CDXs participate in the pathogensis of colon cancer. In 
Cdx2+/− mice, reduced Cdx2 expression does not initate colon tumor, but facilitates 
the tumour progression upon DNA mutant challenge [117]. By overexpressing 
CDX2 in a colon cancer cell line HT29, Mallo et al. have found that CDX 
overexpression reduces the cell growth and tumorigenicity, and inhibits cell migraton 
[118]. In colon cancer, there are other signalling pathways involved in regulating 
CDXs. In colon cancer cell lines with constitutively activated Ras, CDX2 is 
downregulated via PKC, which correlates with PKC-dependent depletion of c-Jun, 
whereas Ras induces the CDX1 expression via a MEK1/MAPK- dependent pathway 
[119]. Phosphatase and tensin homologue (PTEN) is one of the most commonly 
mutated tumor suppressor genes in human, and acts through its phosphatase protein 
product. Mutation or depletion of  PTEN results in an increase of cell proliferation 
and inhibition of cell apoptosis. Kim et al have shown a similar distribution of Cdx2 
and Pten in wild-type and Pten+/- mice. They subsequently showed that Pten can 
stimulate Cdx2 at the mRNA and protein level via the PTEN/P13K pathway, and that 
proinflammatory cytokine TNF-α reduces CDX2 expression via altering the balance 
of NF-κB subunits p50 and p65 [120]. In colorectal cancer cells, oncogenic 
activation of β-catenin can stimulate CDX1 expression [121]. Overall, restoring the 
CDX1 and CDX2 expression may prove to serve as an effecive therapy against colon 
cancer.  
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1.8 BE 
1.8.1 Definition  
BE was first described by Dr. Norman Barrett in 1950. The definition of BE has been 
a topic of debate (Fig 1.4). According to the American Gastroenterology Association 
(AGA) Institute Medical Position in 2011, BE is suspected when “under endoscopic 
examination, columnar epithelium is observed to extend above the gastroesophageal 
junction (GEJ) into the tubular esophagus, BE can be defined conceptually as the 
condition in which any extent of metaplastic columnar epithelium that predisposes to 
cancer development replaces the stratified squamous epithelium that normally lines 
the distal esophagus” [122]. 
 
The presence of IM containing goblet cells is critical for the diagnosis of BE. 
Disagreement between professional societies raises the question of whether it is 
important to include goblet cells in the diagnostic criteria. In the Japanese and British 
guidelines, goblet cells are not essential to establish a diagnosis of BE, largely 
because of sampling error, and difficulties in distinguishing true goblet cells and 
pseudo-goblet cells in pathological terms. It is worth noting that IM without goblet 
cells also predisposes a patient to develop esophageal adenocarcinoma (EAC), 
therefore, it is important to find a non-morphological marker. 
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Fig. 1.4 BE. A. Normal esophagus: squamous epithelial lining of the normal esophagus, B. 
Magnified view of BE tissue shows the columnar lining containing goblet cells. Taken from 
Spechler and Goyal [123]. 
 
1.8.2 Epidemiology   
In Western countries, BE is present in 1.6 % of the general adult Swedish population 
[124]. A cohort study using the general practice research database from the UK 
reported a rise of incidence from 19.8/100,000 (~0.02 %) in 1997 to 40.5/100,000 
(~0.04%) in 2002. The variation in the reported incidences between countries may 
due to the sample population selection and the definition used for BE. However, the 
authors speculate that this rise could be explained by increased awareness of BE and 
improved endoscopic diagnostic skills of endoscopists [125]. Although the 
prevalence of gastroesophageal reflux disease is increasing in Asia, the prevalences 
of BE and EAC has remained low in most Asian compared to Western countries. The 
prevalence varies between countries (reviewed in [126]): In China, a prevalence of 
1 % was found in patients who complained of upper gastrointestinal symptoms, and 
in this study population, age, and esophagitis were further associated with BE [127], 
Japan has been reported to have the prevalence of BE of 19.9 % in patients who 
undergo esophagogastroduodenoscopy [128]. In Korea, BE prevalence was reported 
to be 0.22 % in a retrospective study [129]. However, in a prospective multicenter-
based study in Korea, BE was shown to present in 0.84 % of study population [130].  
 
Overall, the increase of BE prevalence in Asia has probably been due to high-fat diet 
and changes in lifestyle. The west and the east do share common risk factors such as 
male sex, older age, and long duration of reflux symptoms.  
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1.8.3 Risk factors 
1.8.3.1 Gastroesophageal reflux disease (GERD) 
GERD is the primary predisposing risk factor for BE that affects approximately 20 % 
of the population in developed countries. About 10-15 % of patients with GERD 
develop BE [123], which predisposes to EAC: patients with BE are 30-40 times more 
likely to develop EAC [131]. 
1.8.3.2 Alcohol 
Alcohol is a well-established carcinogen responsible for the pathogenesis of many 
cancers. A recent population-based case-control study reports that life-long alcohol 
consumption does not increase the risk of BE, and increased beer intake might in fact 
have a protective role against BE [132]. Similarly, other previous studies also have 
shown that alcohol is not a risk factor for BE, and in this case, recent alcohol 
consumption was also taken into account in the analysis [133]. A prospective cohort 
study in the Netherlands has shown no correlation between alcohol consumption and 
BE [134]. A community-based study has found that the risk of BE was not associated 
with consumption of liquor or beer, and inversely associated with wine intake [135].  
1.8.3.3 Smoking  
A US-based prospective study has shown an increased risk of BE in former smokers, 
and is of the highest risk in heavy and remote smoking [136]. In another study, 
former smokers, but not current smokers were found to be at higher risk of 
developing BE [134]. Smith and colleagues also have shown that smokers have a 
higher risk of developing BE compared to non-smokers [137]. In contrast, Kubo and 
colleagues have not identified smoking as risk factor for BE [138].  
1.9 Current theories of molecular origin of BE 
The first theory suggests a role for stem cells in the pathogenesis of BE. The 
intestinal stem cell marker leucine-rich repeat-containing G protein-coupled receptor 
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5 (LGR5) has been been found to be overexpressed in BE, although the intensity of 
staining is higher in EAC than BE [139].  
 
The second theory suggest that bile salts and acids in the reflux contents of GERD 
cause the tight juctions to break in squamous cells, and allow leakage of the refulx 
contents into the basal layer. These factors can induce CDX1 and CDX2 
transcription factors, causing esophageal cells to transdifferentiate into columnar 
cells (reviewed in [140]), as shown in Fig 1.4.  
 
 
Fig. 1.5 Transformation of squamous esophageal epithelium to BE epithelium. This 
picture shows the transformation of normal squamous esophageal epithelium into BE. After 
chronic exposure to bile salts and acids, the tight junctions become loose, which allows bile 
salts in and the transformation of normal esophageal cells into intestinal-like cells. Taken 
from Scouza et al  [140]. 
The third theory concerns p63, a homologue of the tumor suppressor protein p53. It 
is expressed in the basal or progenitor layers of many epithelial tissues. P63 can act 
as a potent inducer of apoptosis. Stem cells in the basal layer of stratified squamous 
epithelia express high levels of p63 and undergo asymmetric division to enable both 
self-renewal and progression to a stratified multilayer lineage. The latter cells may 
express less p63, and are capable of limited proliferation and self-renewal, but are 
INTRODUCTION  28   
 
 
ultimately destined for terminal differentiation. The absence of p63 results in failure 
to maintain a basal cell population, suggesting a requirement for p63 in the 
regenerative aspect of stem-cell division and for maintenance of a normal stratified 
squamous esophageal epithelium [141]. Wang et al. have studied the molecular 
origins of the role of embryonic cells as precursors of Barrett’s-like metaplasia. The 
study set out to look in a p63-null mouse model, where stem cells undergo self-
renewal in the absence of any mutations. They found that upon programmed damage, 
embryonic cells compete with cells in the proximal stomach, and migrate and replace 
the damaged squamous cells [142]. This contradicts a previously proposed 
mechanism, where metaplasia is formed prior to the damage by transformation of the 
existing tissue [140]. The results of this study have important implications for 
understanding the underlying cause of other gastrointestinal malignancies, such as 
gastric and pancreatic cancer, and IBD [142]. 
   
1.10 BAs and BE  
Excess levels of BAs are toxic and have been shown to be carcinogenic to the 
esophagus, stomach, colon, and liver [143]. In the colon, high levels of DCA can 
induce colon carcinoma in mice [144]. BAs are a major component of duodenal juice, 
which can cause severe esophageal mucosal damage [145]. BA can cause oxidative 
damage, apoptosis, and DNA damage. Acidic bile salts can modulate the squamous 
epithelial barrier by altering the expression levels of claudin 1 and claudin 4 [146]. 
Nehra et al first suggested the damaging effects of BAs in the esophageal mucosa. 
The predominant BAs are CA, TCA and GCA, but in patients with erosive 
esophagitis, BE and esophageal stricture, there is a significantly greater proportion of 
secondary BAs, DCA and TDCA [147]. Furthermore, bile salts and acids exhibit 
different effects on cell proliferation rate. Bile salts alone increase proliferation, 
whereas addition of BAs inhibits proliferation [148].  
 
Xenobiotic-sensing nuclear receptor PXR was found overexpressed in EAC and BE 
in comparison to normal squamous epithelium [149]. Moreover, cytoplasmic staining 
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of PXR was observed in BE, whereas nuclear staining was seen in EAC. The 
translocation of PXR from cytoplasm to nuclei was confirmed in an esophageal cell 
line OE19, induced by LCA or rifampicin [150]. FXR is also overexpressed in BE 
compared to normal esophageal mucosa and decreased in EAC, and the FXR 
antagonist guggulsterone induces apoptosis in BE cell lines [151]. A similar study 
has shown that, in addition to FXR, the levels of its target genes SHP and IBABP are 
increased in BE columnar epithelium compared to normal squamous epithelium, and 
FXR and IBABP levels can be induced exogenously by DCA in esophageal cell lines. 
In the same study, interleukin-8 (IL-8) and macrophage inflammatory protein-3α 
(MIP3α) levels are also elevated. These data suggest that BAs can induce an immune 
response [152]. To further emphasize the role of BA transporters in BE pathogenesis, 
Dvorak et al. have demonstrated that ASBT, IBABP, and MRP3 are elevated in BE 
and decreased in EAC, at both the mRNA and protein levels [153].  This is another 
adaptive response mechanism of the columnar mucosa against GERD. The BA 
receptor TGR5 was found to be expressed in BE and EAC, whereas only a minimal 
amount can be detected in normal esophageal mucosa. TGR5 mediates TDCA-
induced expression of the NADPH oxidase isoform NOX5-S and H2O2 production 
[154]. Overall, these findings illustrate the local cellular changes that take place in 
response to the contents of chronic reflux. 
 
1.11  Transcription factors associated with BE: p53, NF-κB, 
CDX1, and CDX2 
Overexpression of the p53 protein has been reported in patients with BE [155]. 
Weston et al. have reported that p53 protein overexpression is more significantly 
associated with BE progression to high-grade dysplasia [156]. In a similar study by 
Skacel et al., p53 positivity was correlated with progression to high-grade 
dysplasia/carcinoma [157].  
 
NF-κB is a transcription factor that controls cell proliferation and survival. NF-κB is 
activated in EAC and its absence can be used to determine response to neoadjuvant 
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chemotherapy and radiation therapy, and low pH and DCA can induce NF-κB DNA-
binding activity [158]. In an OE33 cell line-based study, DCA can cause DNA 
damage, and can also induce NF-κB activity [159]. 
 
CDX2 is expressed in patients with BE and inflammatory esophageal mucosa [125, 
126]. Several studies have confirmed the elevated expression of CDX1 and CDX2 in 
BE and inflammatory esophageal mucosa in comparison to normal esophageal 
mucosa, at both the mRNA and protein levels [160]. In a microarray study, CDX1 
and CDX2 expression were found to be differentially upregulated in BE, a finding 
also confirmed using IHC [161]. These data suggest that CDXs are involved in the 
pathogenesis of BE. Furthermore, CDX1 and CDX2 expression were induced in a 
bile acid-specific manner. DCA and CA show strongest activation of the CDX2 
promoter via NF-κB, whereas the remaining BAs have no stimulatory effect [162]. 
As demonstrated in a rat model of BE, mixture of BAs, including CA, GCA, and 
TCA, can activate CDX1, and in esophageal derived cell lines, CDX1 and CDX2 
exhibit homologous auto-regulation and heterologous inter-regulation [106].  
 
1.12 Other cellular changes in BE 
Other cellular changes in BE include alterations in the cell cycle, cellular architecture, 
and proliferation rate. Cyclin D1 expression is increased at the protein level [163], 
and this may prove to be a useful predictive biomarker for the development of EAC 
in BE patients [164]. The antigen Ki-67 is a nuclear protein marker of cell 
proliferation, and can be detected in the cell nuclei during interphase. Nuclear 
localization of Ki-67 in BE with low grade dysplasia (LGD) can be found in the 
lower crypt, whereas in BE with high grade dysplasia (HGD) the Ki-67 protein is 
found located in the upper crypt and surface epithelial zones [165] 
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1.13 Helicobacter pylori and BE   
H. pylori is a Gram-negative bacterium and is a major cause of duodenal and gastric 
ulcers and stomach cancer. Vaezi et al. showed that colonization with CagA-positive 
strains of H. pylori is more common in healthy people and GERD patients than in BE 
patients, which suggests a protective role against malignant disease [166].  
1.14 Cyclo-oxygenase 2 (COX2) and BE 
COX2, or prostaglandin endoperoxide synthase 2, is encoded by PTGS2 gene, and is 
involved in prostglandin synthesis. COX2 is constitutively expressed in most cells 
under normal conditions, and its expression can be induced by inflammation.  
Elevated COX2 and inducible nitric oxide synthase (iNOS) mRNA and protein levels 
in BE indicate their involvement in early pathogenesis [167], and the levels increase 
during progression from low-grade to high-grade dysplasia [168]. In addition, pulses 
of acids or BAs enhances COX2 expression in BE tissue explants, which can be 
attenuated by the COX2 inhibitor NS-398 [169]. Similar findings have been shown 
in Barrett’s-associated adenocarcinoma cell lines [170]. Another COX2 inhibitor, 
rofecoxib, is active against esophageal dysplasia and adenocarcinoma [171]. COX2 
expression is negatively associated with the survial of patients undergoing surgery 
for EAC [172]. 
 
1.15 Inflammation in BE 
Inflammatory pathways are associated with the development of BE. Proinflammatory 
cytokines IL-8 and IL-1β are elevated in esophagitis, BE, and EAC [173]. DCA 
activates the transcripton factor NF-κB at neutral pH and subsequently its 
downstream targets IκB and IL-8 in a BE cell line OE33 [174]. 
 
TNF-α is a cytokine released by immune cells and other cell types, causing 
inflammation. There is an increase in TNF-α expression in the progression of 
Barrett’s metaplasia to adenocarcinoma, and upregulation of TNF-α induces 
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expression of the c-myc oncogene via β-catenin in an NF-κB-independent manner 
[175].  
 
1.16 Signalling pathways in the pathogenesis of BE 
It is well established that multiple cell signalling pathways are altered during the 
course and progression of BE. Elucidating the altered pathways during disease 
progression may provide insight into future treatment or adjuvant treatment strategies.  
 
Epidermal growth factor receptor (EGFR) exists on the cell surface and is activated 
by binding of its specific ligands, including EGF and transforming growth factor-α 
(TGF-α). Both EGFR and TGF-α are expressed in the inflamed tissue in BE [176, 
177]. DCA can induce CDX2 expression in esophageal cells via the EGFR signalling 
pathway [178]. EGFR expression has been shown to increase as the disease 
progresses form BE, to low-grade dysplasia, high-grade dysplasia, and EAC, which 
makes it a potential biomarker candidate for predicting esophageal cancer risk [179]. 
 
The MAPK signalling pathway plays roles in cellular differentiation, development, 
transformation and apoptosis. Patients with GERD have a lower level of ERK1/2 
phosphorylation, and acid exposure can increase ERK1/2 expression levels and their 
phosphorylation status [180]. Kinome profiling of BE and paired squamous 
esophageal tissue has shown that EGFR activity was decreased in BE compared to 
normal squamous tissues, and MAPK is downregulated in BE in comparison to its 
surrounding tissues [181]. 
 
BRAF and KRAS2 mutations are found in Barrett’s adenocarcinoma, implying that 
disruption of the RAF/MEK/ERK (MAPK) kinase pathway is involved in the early 
development of BE [182]. The transforming growth factor-β (TGF-β) is 
constitutively expressed in healthy esophageal epithelium, but becomes progressively 
more overexpressed in inflamed GERD tissue, metaplastic BE epithelium, and EAC 
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[183]. The Ski and SnoN proteins negatively regulate TGF-β via interaction with the 
SMAD complex and recruitment of histone deacetylases [184]. Ski and SnoN 
proteins are absent in normal esophageal epithelium, but strongly expressed in BE 
epithelium. Upon disease progression, Ski and SnoN expression decreases in low-
grade dysplasia and becomes absent in EAC [185]. Their high expression in BE may 
indicate that they are involved in aberrant TGF-β signalling in this disease. 
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1.17 Protein-protein interactions (PPIs) 
A useful way to gain insight into the function of a protein of interest is to study other 
proteins that it interacts with. PPIs form the basis of cellular and biological processes 
and signal transduction. Several methods have been developed in the past two 
decades for identification of protein partners [186, 187]. DNA-binding transcription 
factors recruit transcriptional cofactors that may act by opening up the chromatin, 
assisting in recruitment of RNA polymerase, or altering the chromatin structure via 
histone modifications. The cofactor proteins can be coactivators or corepressors that 
function in conjunction with the known transcription factor. The role of CDX factors 
in intestinal differentiation and their aberrant expression levels in IM are well 
established. However, little is known about the exact molecular mechanisms by 
which CDXs exert their function as transcriptional activators or repressors. Thus, I 
carried out large-scale screening to identify novel protein-interacting partners of 
CDXs that may mediate or modulate their transcriptional activity. A previously 
described coactivator of CDX2 is p300, which is involved in the transcriptional 
regulation of the proglucagon gene [188].  
1.17.1 Far western (FW) screening 
FW screening has been successfully used for cloning several important protein 
molecules that interact with the proteins of interest: Proteins that interact with 
BRCA1 [189], RB-binding partners such as the retinoblastoma binding protein-1 
(RBP-1) [190], and the c-Myc interacting partner Max [191]. 
In FW screening, a cDNA expression library is first constructed from mRNA of 
tissue(s) of interest. The library is then ligated to the lambda phage vectors, which 
are used to transduce host bacteria. After this, the phage-containing bacteria are 
plated on screening dishes, and protein expression is induced. The induced proteins 
are immobilized on the solid surface support, typically transferring them onto 
nitrocellulose filters. The membranes are then blocked to prevent non-specific 
background, probed with the protein of interest, and finally washed to remove 
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unbound proteins. The most commonly used baits are in vitro translated proteins 
radioactively labelled with 35S, so that the positive signals can be detected by 
exposing on films.  
Compared with the two-hybrid system, the advantages of far western blotting are that 
it can use untagged bait and target proteins and it generally produces few false-
positive results. Its disadvantages are the lack of eukaryotic modifications of target 
proteins, the use of radioactive reagents, potential lack of eukaryotic protein folding, 
and that only binary complexes can be detected, similarly to the yeast two-hybrid 
screening. The success of the FW screening depends on the quality of the bait and 
the representation (amplified or not) of the bacteriophage cDNA library. The strength 
of interaction between bait and prey ultimately determines the outcome. 
1.17.2 Yeast two-hybrid (YTH) screening 
YTH screening was first described in 1989 [192] by Fields and Song. It is an in vivo 
genetic assay, which is taking place in the nuclei of the yeast. The assay is based on 
the bait protein being fused to the DNA-binding domain of the transcription factor 
Gal4 or LexA, and the prey proteins are fused to the strong transactivation domain of 
a transcription factor. Only when DNA-binding and transactivating domain are 
physically reconstituted, the activation of a downstream reporter gene is detected 
either by growth under selective medium or a color signal will take place [193, 194].  
Host organisms have also been expanded to bacteria [195] and mammalian cells [196, 
197]. One of the disadvantages of the two-hybrid screening is the high percentage of 
false positives. Also, false negative interactions resulting from improper protein 
folding, and lack of mammalian post-translational modifications may pose problems 
[198, 199].  Lack of physiological relevance may be an issue, because the PPI 
identified does not happen in the real biological setting, and this requires follow up 
experiments to validate the true interaction. However, this is a problem presented 
also in other screening methods. The advantage of YTH is that it is very sensitive 
and can thus also detect transient interactions.  
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1.17.3 Protein microarrays 
In comparison to the traditional approach, protein microarrays have revolutionized 
the speed of discovery on a larger scale. It is a relatively new technology offering a 
platform for diagnostic and prognostic biomarker discovery, and protein interactome 
studies of transcription factors. The reaction takes place on a protein chip contains up 
to 9000 full-length and active proteins that represent a wide range of kinases, nuclear 
receptors, phosphatases, membrane proteins, transcription factors, that are 
immobilized on nitrocellulose coated glass microscope slides. Bound proteins can be 
detected via probes that are labelled with fluorescent, affinity, photochemical, or 
radioisotope tags [200, 201].  
1.17.4 Co-immunoprecipation (co-IP) 
The process of IP works by adding a specific antibody to a known protein to cell 
lysates or mixture of proteins. Thus, the antigen can be precipitated , and any 
proteins that bound to the antibody is washed and eluted. Then, the proteins can be 
separated on SDS-PAGE and studied further by western blot or by protein 
sequencing. The advantage of this approach is that protein interaction partners are 
not limited to binary bindings, but more complex protein complexes can be identified. 
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2 AIMS OF THE STUDY 
 
The present research was centered on the intestine-specific transcription factors caudal-
type homeobox proteins CDX1 and CDX2, which function to maintain intestinal 
phenotype, differentiation, and proliferation. I investigated the regulation of the promoter 
regions of genes encoding intestinal BA transporters, ASBT and OSTα/β. They are 
components of the enterohepatic circulation for bile acids, and are found expressed in the 
terminal ileum. ASBT and OSTα/β are crucial for BA uptake and efflux in enterocytes, 
respectively. Their transcriptional regulatory mechanisms of genes encoding them have 
been previously studied, but it was not known, whether the intestine-specific transcription 
factors CDX1 and CDX2 play additional roles. To emphasize the pathophysiological 
relevance of this regulation in a disease setting, recent evidence has shown that expression 
of three BA transporters - ASBT, MRP3, and IBABP - is elevated in esophageal epithelial 
cells from patients with BE, further emphasizing the relevance of this regulation in a 
disease setting. However, the precise mechanisms that mediate the aberrant expression of 
the ASBT transporter gene in BE were not known. The following questions were addressed: 
 
• What are the transcriptional regulatory mechanisms of the ASBT promoter regulation 
with regard to CDX1 and CDX2 in cultured cell lines and human ileal and esophageal 
biopsy specimens? 
 
In addition to the known transcriptional regulatory mechanisms described above for the 
OSTα/β genes, we hypothesized that tissue co-expression of the intestinal transcription 
factors CDX1 and CDX2 may also play a role in the regulation of OSTα/β expression. The 
aim of the second part of the present work was to investigate the detailed transcriptional 
regulation of the OSTα/β  genes with regard to CDX1 and CDX2, and also whether 
OSTα/β are detectable in BE biopsies. 
 
• What are the transcriptional regulatory mechanisms of the OSTα/β promoters with 
regard to CDX1 and CDX2 in cultured cell lines and esophageal biopsy tissue? 
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Another focus of the presented work was to identify novel co-activators and co-repressors 
of CDX1 and CDX2 by Far Western screening. 
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3 MATERIALS AND METHODS 
 
3.1 Chemicals 
Deoxyadenosine 5′-[α-32P]-triphosphate (6,000 Ci/mmol) and EasyTag™ EXPRESS35S 
Protein Labeling Mix, [35S]-,7mCi (259MBq) were purchased from Perkin Elmer 
(Schwerzenbach, Switzerland). Restriction enzymes were from Roche Diagnostics 
(Rotkreuz, Switzerland), and PuReTaq Ready-To-Go PCR beads from GE Healthcare 
(Glattbrugg, Switzerland). The oligonucleotides (Appendix, Table 1) were synthesized by 
Microsynth (Balgach, Switzerland). SMART cDNA Library Construction Kit was from 
Clontech (Mountain view, CA, USA). Other chemicals were purchased from Sigma-
Aldrich (Buchs, Switzerland), unless stated otherwise. 
 
3.2 Cell culture 
All cell lines were obtained from (LGC Promochem, Molsheim, France), unless otherwise 
stated. Human esophagus-derived cell line Het-1A was cultured in Bronchial Epithelial 
Cell Growth Medium (BEGM) supplemented with SingleQuot kit (Lonza, Basel, 
Switzerland). Human esophageal OE19 cells were cultured in RPMI-1640 + 2 mM L-
glutamine. Human colon-derived T84 cells were cultured in Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture F-12 (DMEM/F-12; Invitrogen, Basel, Switzerland), Caco-2 
cells in DMEM (Sigma-Aldrich), and LS174T cells in Minimal Essential Medium (MEM; 
Sigma-Aldrich). DLD1 cells were cultured in RPMI-1640 (Invitrogen). All media for cell 
lines, except Het-1A, were supplemented with 10 % fetal bovine serum (FBS; Brunschwig, 
Basel, Switzerland), and 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen). The 
epithelial cell line IEC-4.1 [202] (a kind gift from Dr. Anthony Jevnikar, Canada), derived 
from small intestines of BALB/c mice, was cultured on collagen-coated plates in 
DMEM/F-12 (1:1) supplemented with 5 % FBS, 1 mM sodium pyruvate, 10 ng/ml 
epidermal growth factor (EGF), and antibiotics as above. All cells were cultured in a 
humidified atmosphere containing 5 % CO2 at 37°C.  
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3.3 Transfection of cells with siRNAs or plasmids, followed by RNA 
isolation 
Cells were seeded at 106 per well in six-well plates, and transfected with hCDX1 
SiGenome SMARTpool (Dharmacon, Lafayette, CO, USA), hCDX2 SiGenome 
SMARTpool, or siCONTROL non-targeting siRNA #2 (Dharmacon), at a final 
concentration of 50 nM using the TransIT-TKO reagent (Mirus Bio LLC, LabForce, 
Switzerland). The transfections were repeated after 24 h, and the cells were harvested in 1 
ml TRIzol (Invitrogen) 24 h after the second transfection. To study the effect of CDX 
overexpression on endogenous ASBT mRNA expression, OE19 cells were seeded on 12-
well plates at the density of 2.5x105 cells/well the day before transfections. Cells were 
transfected with 2.5 µg of either pcDNA3.1 vector control or 2.5 µg of either CDX 
expression construct, using 3 µl of the Fugene HD transfection reagent (Roche 
Diagnostics) per microgram of plasmid DNA. Twenty-four hours later, cells were 
harvested in 0.5 ml of TRIzol/well, and RNAs were processed as described above. 
3.4 Reverse transcription, and real-time PCR 
Four micrograms of RNA isolated with TRIzol reagent were reverse transcribed with High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Rotkreuz, Switzerland), 
before the real-time PCR analysis using the TaqMan assays Hs00156451_m1 (CDX1), 
Hs00230919_m1 (CDX2), Hs00166561_m1 (ASBT), Hs00380895_m1 (OST-α), 
Hs00418306_m1 (OST-β), Hs00167041_m1 (HNF-1α), Hs00200229_m1 (villin), or 
human ACTB (β-actin) endogenous control (Applied Biosystems), on a 7900HT Fast Real-
Time PCR system (Applied Biosystems). The relative mRNA levels were calculated by the 
comparative threshold cycle method. Within an experiment, all tests were performed in 
triplicates. 
 
3.5 Reporter gene constructs and expression vectors 
The human CDX1 and CDX2 expression constructs (kind gifts from Dr. Juan Lucio 
Iovanna, France) in the pcDNA3.1 vector (Invitrogen) were created as described 
previously [118]. Mutations in the constructs were corrected to wild-type by site-directed 
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mutagenesis (QuikChange; Stratagene, La Jolla, CA, USA). Cloning of the human ASBT (-
1688/+525) [45] and ASBT (-830/+525) [44] promoter constructs has been described 
previously. Cloning of the human OSTα (-1475/+161) and OSTβ (-4748/+29) promoter 
reporter constructs has been described previously [18]. The human ASBT promoter 
fragment -99/+525 was amplified using oligonucleotides shown in Table 1, with the 
promoter construct ASBT (-1688/+525) as the template. The PCR fragment was cloned into 
the pGEM-T vector (Promega, Dübendorf, Switzerland), and further subcloned into the 
pGL3basic vector (Promega). Point mutations were introduced into the ASBT (-830/+525) 
construct construct using the QuikChange site-directed mutagenesis kit (Stratagene, Basel, 
Switzerland) and oligonucleotides listed in Appendix Table 1. The mouse Asbt promoter 
fragment (-1810/+3) and the rat Asbt promoter fragment (-2975/+147) were cloned from 
mouse or rat, respectively, genomic DNA (Clontech), using the PCR oligonucleotides 
shown in Appendix Table 1. Both PCR products were cloned into the pGEM-T vector, and 
further subcloned into the pGL3basic vector. To create the pTNT-CDX constructs for in 
vitro translation, the CDX1 and CDX2 cDNA fragments were cut out from the pcDNA3.1 
constructs with EcoRI, and subcloned into the EcoRI restriction site of the expression 
vector pTNT (Promega). The identities of all PCR-cloned fragments were verified by DNA 
sequencing (Microsynth).  
 
3.6 Transient plasmid transfections and luciferase reporter assays 
For reporter assays, cells were seeded on 48-well plates at a density of 105/well for Caco-2, 
LS174T and T84 cells, or 50,000 cells/well for Het-1A, OE19, and IEC-4.1 cells, 24 h 
before transfection. Cells were cotransfected with 400 ng of the luciferase reporter 
constructs and 200 ng of the expression plasmids at a ratio of 3 µl FuGENE HD per µg 
DNA. To normalize the amount of DNA transfected, the pcDNA3.1(+) vector was added 
when appropriate. To control for transfection efficiency, 100 ng of the Renilla luciferase 
(pRL-CMV) reporter plasmid (Promega) were cotransfected. Cells were harvested 36 h 
after transfection, and luciferase activities determined using the Dual Luciferase Assay 
System (Promega) and a Luminoskan Ascent microplate luminometer (Thermo Fisher 
Scientific, Wohlen, Switzerland). Reporter activities obtained for the empty pGL3basic 
corresponding to each test condition, as well as for the test construct containing the test 
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promoter in the control conditions, were set to 1, and fold activities are shown relative to 
this. All experimental conditions were performed in triplicate and the experiments were 
repeated at least three times. 
 
3.7 Electrophoretic mobility shift assay (EMSA) 
Oligonucleotides used in EMSAs (Appendix, Table 1) were designed to have a 5′-AGCT 
overhang in the top strand and a 5′-GATC overhang in the bottom strand when annealed, 
allowing radioactive labelling by fill-in reactions. Fifty nanograms of annealed 
oligonucleotides were labeled in 20 µl reactions containing 1 µl MultiScribe Reverse 
Transcriptase (50 U/µl) (Applied Biosystems), 1 µl 1× RT Buffer, 250 nM 
dGTP/dCTP/dTTP, and 1 µl [α-32P]-dATP. Unincorporated nucleotides were removed 
using Microspin G-25 columns (GE Healthcare). Six micrograms of LS174T nuclear 
extracts prepared using the NE-PER extraction kit (Pierce, Lausanne, Switzerland) or 1.5 
µl of in vitro translated CDX1/CDX2 proteins each, generated with TNT T7 Coupled 
Reticulocyte Lysate System (Promega), using the plasmids pTNT-CDX1 and pTNT-CDX2 
as templates, were used for each DNA-binding reaction. Protein DNA complexes were 
formed in the binding buffer [20 mM Tris–HCl, pH 8.0, 60 mM KCl, 2 mM MgCl2, 12% 
(v/v) glycerol, 0.3 mM dithiothreitol (DTT), 87.5 ng/µl preboiled poly(dI-dC)-poly(dI-dC)] 
in a total volume of 20 µl for 10 min at 30°C. After this, 50,000 cpm (0.5–1.5 ng) of the 
radioactive probes was added to the reactions. For competition EMSAs, 10-, 50-, or 100-
fold molar excess of unlabelled ASBT promoter CDX-binding site-containing 
oligonucleotides was added immediately before the radioactive probe containing a 
consensus CDX response element (CDXRE). In supershift experiments, 1 µl of the 
monoclonal CDX1 antibody [98] (a kind gift from Dr. Walter Bodmer and Dr. Carol Chan, 
UK), polyclonal CDX2 antibody (C6747; Sigma), polyclonal RXRα antibody (sc-774; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA), or polyclonal PPARα antibody (sc-
1985; Santa Cruz Biotechnology) were added to the extracts 1 h before the probe, and 
incubated at 4°C. Immediately after the binding reactions, the samples were loaded onto 
pre-electrophoresed 5% (acrylamide/bis 30:1) native acrylamide gels and run at 200 V in 
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0.5× TBE for 3 h. The gels were fixed in 10 % (v/v) acetic acid for 10 min, dried onto 
Whatman DE81 paper under vacuum, and exposed to Kodak BioMax MR-1 films at -80°C. 
 
3.8 Chromatin immunoprecipitation (ChIP) assays 
ChIP assays were carried out as described previously [203]. T84 cells were grown on 10 
cm plates to 80% confluence, and the cells were harvested by crosslinking with 1% 
methanol-free formaldehyde and processed using the ChIP-IT Express kit (Active Motif, 
Rixensart, Belgium). Shearing of the chromatin was achieved by five 20 s pulses of 
sonication with 30 s pauses on ice between each pulse, using a Branson Digital Sonifier 
(Branson Ultrasonics, Danbury, CT, USA) at a power setting of 25 %. For 
immunoprecipitations, the samples were incubated with 2 µg negative control mouse IgG1 
antiserum (Dako Denmark A/S, Glostrup, Denmark), or with 2 µg of one of the following 
antibodies: anti-CDX1 (CDX1 Ab1), anti-CDX1 (ab24000; Abcam, Cambridge, UK) 
(CDX1 Ab2), anti-CDX2 (71-83; Sigma) (CDX2 Ab1), anti-CDX2 (MU392A-100; 
Biogenex, Fremont, CA, USA) (CDX2 Ab2). Two amplicons were assayed for 
immunoprecipitated samples, using the oligonucleotide primers listed in Table 1, 
containing either the ASBT promoter region (-736/-154) or a region from the first intron of 
the ASBT gene. After the initial denaturation stage at 94°C for 3 min, the PCR cycling 
conditions were 94°C for 20 s, 60°C for 30 s, and 72°C for 1 min. For the ASBT promoter 
region, 5 µl of each PCR product was removed after 38 cycles, and for the ASBT intron 
fragment, 5 µl of each PCR product was removed after 30 cycles. The ASBT promoter and 
intronic PCR fragments were resolved on 1.5 % agarose gels, containing GelRed gel stain 
(Chemie Brunschwig AG, Basel, Switzerland). 
 
3.9 Human tissue collection and processing 
Signed informed consent forms were collected from all human subjects. The study protocol 
and consent forms were approved by the Ethical Committees of the sample collection sites. 
A total of 35 patients were included in the study. BE tissue was collected in 2011 at the 
Department of Gastroenterology, Qingdao Municipal Hospital, China; Department of 
Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of 
MATERIALS AND METHODS  44   
 
 
Medicine, Shanghai, China; Division of Gastroenterology, Chinese PLA General Hospital, 
Beijing, China, and Department of Gastroenterology, General Hospital of Chinese People’s 
Armed Police Forces, Beijing, China. BE was diagnosed endoscopically and histologically 
on the basis of typical features such as the presence of specialized columnar epithelium and 
goblet cells. An experienced local pathologist performed histology. Of the 35 patients, 22 
(63%) were male and 13 (37%) were female. The mean age ± SD of the cohort was 52.60 
±10.97 years, and the median age was 52 years. Among the patients, 29/35 (83%) had 
detectable CDX1 mRNA expression, all 35 had detectable CDX2 expression, and 20/35 
(57%) had detectable ASBT expression. The BE samples were homogenized by ultrasound. 
RNAs were isolated using the TRIzol reagent (Invitrogen), and were quantified with a 
NanoDrop ND-1000 spectrophotometer (Witec AG, Littau, Switzerland). Ileal biopsies 
were obtained from 48 healthy patients during routine surveillance colonoscopies in the 
endoscopy unit of the Division of Gastroenterology and Hepatology at the University 
Hospital Zurich between 2004 and 2008. Of these 48 patients, 17 (35%) were male and 31 
(65%) were female. The mean age ± SD of the cohort was 54.3±13.7 years, and the median 
age was 58.5 years. Ileal samples were collected in RNAlater (Ambion, Austin, TX, USA), 
and syringed into TRIzol reagent before RNA isolation. RNAs were quantified with a 
NanoDrop ND-1000 spectrophotometer. 
 
3.10 In silico analysis of the ASBT, OSTα , and OSTβ  promoter regions 
I performed an in silico analysis on the proximal 850 base pairs of the human ASBT, 927 
base pairs on OSTα and 1453 base pairs on OSTβ proximal promoter (NCBI Reference 
Sequence: NT_009952.14; NT_029928; NW_925884), to identify putative CDX response 
elements (CDXREs). The consensus core motif for CDX DNA-binding is 5′-TTTAT/C -3′ or 
5’-G/ATAAA-3′ [86]. CDXREs within the proximal promoter region were identified by 
MatInspector software [204] and visual inspection.  
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3.11 Immunohistochemistry 
For the evaluation of ASBT and CDX protein expression in formalin-fixed paraffin-
embedded tissues, standard immunohistochemical assays involving biotin-avidin-linked 
peroxidase detection were used. Paraffin-embedded sections were dissolved by placing the 
glass slides on heating blocks for 10 min. Slides were deparaffinized by two 5 min changes 
of xylene. The sections were dehydrated through a graded series of 80 %, 95 %, and 100 % 
ethanol, washed three times in PBS, and placed in 0.5 % H2O2 for 30 min to block 
endogenous peroxidase activity. Antigen retrieval was performed by immersing slides in 
10 mM citrate buffer, pH 6.0, placing them in a pressure cooker until boiling point, and 
then allowing them to sit for 5 min. Slides were taken out and rinsed three times with PBS 
at 3 min intervals. Slides were incubated overnight at 4°C with rabbit polyclonal anti-
ASBT antibody at a final concentration of 1:400 (a kind gift from Paul Dawson, Wake 
Forest University Baptist Medical Center, Winston-Salem, NC, USA), anti-CDX2 
antibody at a final concentration of 1:200 (Maixin MAB-0216, China), or anti-CDX1 at a 
final concentration of 1:200 (AP6130a; Abgent, San Diego, CA, USA). Slides were again 
rinsed with PBS and biotinylated secondary antibodies were added and incubated at room 
temperature for 1 h. Slides were taken out and rinsed three times with PBS at 3 min 
intervals and lightly counter-stained with hematoxylin. 
 
3.12 Statistical analysis 
All cell-based experiments were independently repeated at least three times, and 
representative experiments are shown. All quantitative data are reported as means ± SDs. 
Differences between experimental groups were analyzed by one-way analysis of variance 
(ANOVA) with Tukey’s post hoc test. P values <0.05 were considered significant. For the 
correlation of mRNA expression levels in human tissue, logarithmic values of mRNA 
levels were analyzed using linear regression. All statistical analysis was carried out using 
GraphPad Prism software (GraphPad, San Diego, CA, USA). 
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3.13 Recipes of media and buffers used in far western screening 
 1 M MgSO4     12.02 g/100 ml H2O (Filter-sterilized) 
 
 10× Lambda dilution buffer    1 M NaCl 
        0.1 M MgSO4.7H2O   
0.35 M Tris–HCl, pH 7.5 
 
 1× Lambda dilution buffer   dilute the stock from above 1:10  
0.01 % gelatin  
 
 MgSO4 plates      LB agar +10 mM MgSO4  
 
 LB/ MgSO4 soft top agar  (1L)   10 mM MgSO4 (10mM final conc.) 
7.2 g agarose 
 
 IPTG 10 mM in H2O 
 
 XL1-blue growth medium    LB medium 
10 mM MgSO4 
0.2 % maltose  
15 µg/ml tetracycline 
 
 Pre-probing buffer    1× binding buffer 
  0.3 mM DTT  
0.05 mg/ml human placental DNA 
(boiled at 98°C for 4-5min and cooled 
to room temperature) 
Complete protease inhibitors (Roche 
Diagnostics): 1 tablet/200 ml 
 
 5× binding buffer     100 mM Tris–HCl, pH 8.0  
300 mM KCl  
10 mM MgCl2  
60 % glycerol 
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3.14 Preparation of  35S-labelled proteins  
In vitro translation of CDX1 and CDX2 proteins was carried out using TNT Quick 
Coupled Transcription/Translation Systems (Promega, USA) with the following 
components: 500 µl TNT Rabbit Reticulocyte Lysate, 40 µl TNT Reaction Buffer, 20 µl 
TNT RNA Polymerase (T7), 20 µl 1 mM Amino Acid Mixture Minus Cysteine and 
Methionine, 80 µl Promix [L]-35S-Met/Cys, 20 µl (40 U/µl) RNasin Ribonuclease inhibitor, 
40 µl (1 µg) DNA templates, and 280 µl of nuclease-free water to a final volume of 1000 µl. 
The reaction was incubated at 30°C for 90 min.  
 
3.15 Purification of the in vitro translated proteins 
To remove excess radioactive amino acids and thus to reduce the background after film 
exposure, Microcon centrifugal filter units (Millipore, Billerica, MA, USA), with a protein 
cutoff size of 10 kDa, were used. Therefore, any molecules smaller than 10 kDa were 
removed. Two hundred microliters of CDX1 or CDX2 proteins were mixed with 200 µl of 
far western binding solution, and loaded on the Microcon spin column at a speed of 13,000 
g for 1 h. The washing step with FW binding solution was repeated three times. 
 
3.16 Protein identity confirmation  
Protein concentrations of purified samples were determined with the BCA protein assay 
reagent (Thermo Scientific). Two microliters of proteins from purified in vitro translated 
CDX1 and CDX2 protein samples were mixed with 8 µl PBS. Proteins were separated on 
10 % SDS-polyacryamide gels, which were then fixed in the following solutions: 50 % 
methanol + 10 % acetic acid for 15 min, 10 % methanol + 5 % acetic acid for 10 min, and 
10 % glycerol for 5 min. The gels were then dried onto Whatman 3MM paper. After 
exposure to films, actual protein sizes were compared to the predicted protein sizes of 
CDX1 and CDX2. 
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3.17 cDNA library construction from human small intestine and colon 
(all procedures described in this section are modified based on the Clontech Laboratories 
cDNA library construction kit user manual) 
 
3.17.1 First-strand cDNA synthesis 
The following reagents were combined in a sterile 0.5 ml microcentrifuge tube: 0.5 µl 
small intestine poly A + RNA, 0.5 µl colon poly A + RNA (Clontech), 1 µl SMART IV 
Oligonucleotide, 1 µl CDS III/3′ PCR Primer, and 2 µl water to a final volume of 5 µl. The 
contents were mixed and incubated at 72°C for 2 min, and cooled on ice for 2 min. The 
following were added to each reaction tube: 2 µl 5× First-Strand Buffer, 1 µl 20 mM DTT, 
1 µl 10 mM dNTP Mix, and 1 µl MMLV Reverse Transcriptase to a final volume of 10 µl. 
The contents of the tube were mixed by gentle pipetting and briefly centrifuged to bring 
the contents down. The tubes were then incubated at 42°C for 1 h, and placed on ice to 
terminate first-strand synthesis. 
 
3.17.2 cDNA amplification by long-distance PCR 
The following components were combined in the reaction tube: 1 µl First-Strand cDNA, 40 
µl deionized water, 5 µl 10× Advantage 2 PCR Buffer, 1 µl 50X dNTP Mix, 1 µl 5′ PCR 
Primer, 1 µl CDS III/3′ PCR Primer, and 1 µl 50× Advantage 2 Polymerase; topped up 
with water to a final volume of 50 µl. The contents were briefly mixed and amplified with 
the following program 1 cycle of 95°C for 1 min, 20 cycles of 95°C for 15 s and 68°C for 6 
min.  
 
3.17.3 Proteinase K digestion 
Fifty microliters of amplified double-stranded cDNA (2-3 µg) and 2 µl proteinase K (20 
µg/µl) were added to a sterile 0.5 ml tube. The sample was mixed and centrifuged briefly 
to bring the contents down, and incubated at 45°C for 20 min. Fifty microliters of 
deionized water was added to the tube. One hundred microliters of 
phenol:chloroform:isoamyl alcohol were added and mixed by continuous gentle inversion 
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for 1-2 min. The tube was centrifuged at 14,000 rpm for 5 min to separate the phases. The 
top phase (aqueous) layer was moved to a clean 0.5 ml tube, and the interface and lower 
layers were discarded. One hundred microliters of chloroform:isoamyl alcohol was added 
to the aqueous layer, which was mixed by continuous gentle inversion for 1-2 min, 
followed by centrifugation at 14,000 rpm for 5 min to separate the phases. The top 
(aqueous) layer was moved to a clean 0.5 ml tube, and the interface and lower layers were 
discarded. Ten microliters of 3 M sodium acetate, 1.3 µl glycogen (20 µg/µl) and 260 µl 
95% ethanol at room temperature were added, followed by centrifugation at 14,000 rpm 
for 20 min at room temperature. 
  
3.17.4 SfiI digestion 
The following were mixed in a tube and incubated at 50°C for 2 h: 79 µl cDNA, 10 µl 10× 
SIFI Buffer, 10 µl SfiI restriction enzyme, and 1 µl 100× bovine serum albumin. The 
incubation was followed by addition of 2 µl 1% xylene cyanol dye (0.1 g in 10 ml water). 
 
3.17.5 cDNA size fractionation by CHROMA SPIN-400 
Sixteen 1.5 ml tubes were labelled and arranged in a rack in order. To prepare the 
CHROMA SPIN-400 Column for the drip procedure, the columns were inverted several 
times to resuspend the gel matrix completely and to remove any air bubbles. A 1 ml 
pipettor was used to resuspend the matrix gently, avoiding generating air bubbles. The 
bottom cap was removed and the column was allowed to drip by gravity. The storage 
buffer drained through the column by gravity flow until I could see the surface of the gel 
beads in the column matrix. The top of the column matrix should be at the 1.0 ml mark on 
the wall of the column. The flow rate should be approximately 1 drop/40-60 s. The volume 
of one drop should be approximately 40 µl. If the flow rate was too slow (i.e., more than 1 
drop/100 s) and the volume of one drop was too small (i.e., <25 µl), the matrix should be 
resuspended completely and the drip procedure repeated until it reached the above 
parameters. 
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When the storage buffer stopped had dripped out, I carefully added (along the column 
inner wall) 700 µl column buffer to the top of the column and allowed it to drain out. When 
this buffer stopped dripping (after 15-20 min), I carefully and evenly applied ~100 µl 
mixture of SfiI-digested cDNA and xylene cyanol dye to the top-central surface of the 
matrix. Before proceeding to the next step, the sample was allowed to be fully absorbed 
into the surface of the matrix. With 100 µl column buffer, I washed the tube that contained 
the cDNA, and gently applied this material to the surface of the matrix. I allowed the 
buffer to drain out of the column until there was no liquid left above the resin. When the 
dripping ceased, I proceeded to the next step. At this point, the dye layer should be several 
millimeters into the column. I placed the rack containing the collection tubes under the 
column, so that the first tube was directly under the column outlet. The total of sixteen 
drops (fractions) was collected. To this end, I added 600 µl column buffer and immediately 
began collecting single-drop fractions (~35 µl per tube) in tubes 1–16. Each tube was 
capped after each fraction was collected, and the column was re-capped after fraction 16 
had been collected. 
 
The following reagents were added to the tube with 3-4 pooled fractions with size fractions 
between 1-4 kb (judged by agarose gel analysis) containing the cDNA, 1/10 volume 
sodium acetate (3 M; pH 4.8), 1.3 µl glycogen (20 mg/ml), and 2.5 volumes of 95 % 
ethanol (-20°C). The tube was placed at -20°C overnight for better precipitation and 
recovery of cDNA. The tube was then centrifuged at 14,000 rpm for 20 min at room 
temperature. The supernatant was removed with a pipette. The tube was briefly centrifuged 
to bring all the remaining liquid to the bottom. All liquid was removed and the pellet was 
allowed to air dry for ~10 min, and resuspended in 7 µl deionized water and mixed gently. 
The SfiI-digested cDNA was then ready to be ligated to the SfiI-digested, dephosphorylated 
λTriplEx2 Vector. 
3.17.6    Ligation of cDNA to lambda λTriplEx2 vector 
The following components were combined in a tube: 1.5 µl cDNA library, 1 µl  vector 
(500 ng/µl), 0.5 µl  10× ligation buffer, 0.5 µl 10 mM ATP, 0.5 µl T4 DNA ligase, and 1 µl  
deionized water in a final volume of 5 µl. The mixture was incubated at 16°C overnight. 
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3.17.7     Package of ligation to the lambda phage  
The Gigapack III Packaging Extracts (Agilent Technologies, Santa Clara, CA, USA) was 
quickly thawed by holding the tube between the fingers. One microliter of cDNA was 
added immediately to the packaging extract. The contents were mixed by pipette and 
incubated at room temperature for 2 h. Five hundred microliters of SM buffer was added to 
the tube. The tube was centrifuged briefly to sediment the debris, and 20 µl chloroform 
was added. At this stage, the phage could be used for titration. 
3.17.8     Titration of the unamplified library  
Determination of the titer (e.g., plaque-forming units (pfu)/µl) of the unamplified library 
gives an estimate of the number of independent phage clones in the library. A single 
isolated colony from the working stock plate (XL1-Blue) was used to inoculate 15 ml 
LB/MgSO4/maltose broth in a 50 ml test tube or an Erlenmeyer flask. The flask was 
incubated at 37°C overnight while shaking (at 140 rpm) until the optical density (OD600) of 
the culture reached 2.0. The cells were centrifuged at 5,000 rpm for 5 min. The supernatant 
was poured off, and the pellet was resuspended in 7.5 ml 10 mM MgSO4. Appropriate 
dilutions of each of the packaging extracts were made in 1× lambda dilution buffer. As a 
general guideline, an appropriate dilution for an unamplified λ lysate is 1:5 to 1:20. One 
microliter of the diluted phage was added to 200 µl XL1-Blue overnight culture, and the 
phages were allowed to adsorb at 37°C for 10-15 min. Two milliliters of melted 
LB/MgSO4 top agar were added and mixed by rapid inversion, before being immediately 
poured onto 90 mm LB/MgSO4 plates pre-warmed to 37°C. The plates were swirled 
quickly after pouring to allow even distribution of the top agar, cooled at room temperature 
for 10 min to allow the top agar to harden, inverted, and incubated at 37°C for 6-18 h. The 
plates were checked periodically to ensure that plaques were developing. The plaques were 
counted and the phage titer was calculated using the following formula:  
 
pfu/ml =   number of plaques x dilution factor x 103 µl/ml 
            µl of diluted phage plated 
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3.17.9       Determining the percentage of recombinant clones 
To perform blue/white screening in E. coli XL1-Blue, the procedure above for titering an 
unamplified library on LB/MgSO4 plates was followed, except IPTG and X-gal were 
added to the melted top agar before plating the phage/bacteria mixtures. For every 4 ml of 
melted top agar, I used 40 µl each of the 100 mM IPTG and 100 mM X-gal solutions, and 
aimed for 500-1,000 plaques/90 mm plate. Plates were incubated at 37°C for 6-18 h, or 
until plaques and blue colour developed. The ratio of white (recombinant) to blue (non-
recombinant) plaques gave an estimate of recombination efficiency. Successful ligation 
using cDNA synthesized from control poly A+ RNA resulted in at least 80 % recombinants.  
 
3.17.10 cDNA library amplification 
A single isolated colony was selected from the primary working plate of XL1-Blue, and 
used to inoculate 15 ml LB/MgSO4 maltose broth, which was incubated at 37°C overnight 
with shaking (140 rpm). The cells were centrifuged for 5 min at 5,000 rpm, the supernatant 
was poured off, and the pellet was resuspended in 7.5 ml 10 mM MgSO4. The required 
number of LB/MgSO4 agar plates was established, along with the required number of 4 ml 
tubes with 500 µl overnight bacterial cultures and enough diluted lysate to yield 6–7 × 104 
plaques per 150 mm plate. The tubes were incubated in a 37°C water bath for 15 min, and 
4.5 ml melted LB/MgSO4 soft-top agar was added to each tube. The phage/bacteria 
preparation was mixed and poured onto LB/MgSO4 agar plates. The plates were swirled 
quickly, while pouring, to promote even distribution of the melted agar over the plates. The 
plates were cooled at room temperature for 10 min to allow the top agar to harden. The 
plates were inverted and incubated at 37°C for 6-18 h, or until the plaques become near 
confluent (i.e., touching each other). Twelve milliliters of 1× lambda dilution buffer was 
added to each plate, which was then stored at 4°C overnight. The eluted phages were then 
ready to be pooled in 1X lambda dilution buffer to form an amplified library lysate. To this 
end, the plates were incubated at room temperature for 1 h on a platform shaker (~50 rpm), 
after which the λ-phage lysates were poured into a sterile beaker. This formed the pooled, 
amplified library lysate. To clear the phage lysate of cell debris and to lyse any remaining 
intact cells: the phage lysate was mixed well and poured into sterile 50 ml glass  screw-cap 
tubes, and 10 ml chloroform was added to the pooled lysates. The caps were screwed on 
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tightly and the tubes vortexed for 2 min. The tubes were then centrifuged in a Beckman J2-
21 centrifuge at 7,000 rpm (5000 g) for 10 min. The supernatant was collected in new 
sterile 5 ml glass tubes, the caps were tightened, and the tubes were stored at 4°C until 
further use. 
3.17.11 Titration of the amplified library 
To titer the amplified library, I repeated the procedures described for titration of the 
unamplified library (Section 3.17.10). A single isolated colony was selected from the 
working stock plate of XL1-Blue and used to inoculate 20 ml LB/MgSO4/maltose broth 
(without antibiotics). The culture was incubated at 37°C overnight with shaking (140 rpm) 
until OD600 reached 2.0. The cells were centrifuged at 5,000 rpm for 5 min, the supernatant 
was poured off, and the pellet was resuspended in 7.5 ml 10 mM MgSO4. Four LB/MgSO4 
agar plates (90 mm) were warmed and dried. To prepare dilutions of phage lysate (library), 
10 µl of the library lysate was pipette into 1 ml 1× lambda dilution buffer (Dilution 1 = 
1:100); and 10 µl of Dilution 1 was transferred into a second tube containing 1 ml 1× 
lambda dilution buffer (Dilution 2 = 1:10,000).  
 
3.17.12 Primary far western screening 
On the day before screening, E. coli XL1-Blue was inoculated into 50 ml medium without 
tetracycline. The bacteria were pelleted by centrifugation at ~1,500 g for 5 min. The pellet 
was resuspended in 25 ml lambda dilution buffer + 10 mM MgSO4. I took 500 µl of the 
bacterial solution and added 32,000 pfu of the lambda library, and incubated the 
bacteria/phage mixture for 15 min at 37°C. I added 10 ml of top agarose to 580 µl 
bacteria/phage mix poured the resultant mixture onto dry, warmed 15 cm agar/10 mM 
MgSO4 plates. The top agarose was kept at a maximum temperature of 45°C in a water 
bath. The top agar was allowed to harden and the plates were incubated at 37°C for 3-5 h 
until plaques were forming. Hybond-C Extra supported mixed ester nitrocellulose 
membranes were marked with a ballpoint pen or pencil, and soaked in ~50 ml 10 mM 
IPTG solution. As soon as plaques began to appear, one soaked Hybond-C Extra 
membrane was added to each plate avoiding bubbles. The Hybond-C Extra membranes 
were first pad-dried on filter paper if too wet. The Hybond-C Extra membranes (now on 
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the plates) were marked using a needle with asymmetrically arranged holes through the 
membrane and agar. The plates were incubated for 3-4 h and kept at 4°C overnight.   
3.17.13 Membrane blocking and addition of probes 
Two Hybond-C Extra membranes were removed from the plates and placed on top of each 
other in a hybridization bag. It was important that the side with the proteins was against the 
hybridization bag and not the other membrane. The bags were sealed as close to the filters 
as possible. This decreased the volume of buffer and radioactivity needed. I used 10 ml of 
pre-probing buffer per two filters in one bag, and incubated for 30 min at 30°C. The 
radioactive protein probes were then added (~10,000 cpm/ml), and the bags inverted gently 
to mix the contents. The bags were incubated for 1 h at 30°C while shaking gently, and 
then emptied by decanting. The membranes were then washed with wash buffer in the bags 
until the signals on the filters were not notably detected by a Geiger counter. This was 
followed by two washing steps on plastic trays. The membranes were finally dried on 
Whatman 3MM chromatography paper overnight. 
3.17.14 Film exposure    
The dried Hybond-C Extra membranes were exposed on Kodak Biomax MR single films 
for 2-3 days for optimal signal, before the films were developed. 
3.17.15 Alignment of blots   
The blots were aligned with the agar plates using the asymmetric holes earlier made with 
the needle, and the plaques that gave a signal were marked at the bottom of the agar plates. 
The plaques were cut out using plastic 3ml Pasteur pipettes. The cut agar plugs containing 
the selected plaques were placed in 500 µl lambda dilution buffer and eluted at 4°C until 
further use. 
3.17.16 Secondary screening 
On the day before screening, E. coli XL1-Blue was inoculated into 50 ml medium without 
tetracycline. Bacteria (20 ml) were pelleted by centrifugation at ~1,500 g for 5 min, and 
resuspend in 10 ml lambda dilution buffer + 10 mM MgSO4. Then, aliquots of 200 ul of 
the bacterial solution were taken, and approximately 40 pfu from the diluted and titrated 
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eluted phages picked as positives from the primary screen were added, and the mixtures 
plated on 10 cm plates. The bacteria/phage mixtures were incubated at 37°C for 15 min, 
after which 5 ml of melted and cooled top agarose were added to the bacteria/phage 
mixtures. These were then poured onto dry, warmed, 10 cm agar plates containing 10 mM 
MgSO4, taking care to avoid bubbles. The top agarose was kept at a maximum temperature 
of 45°C in a water bath. The top agarose was allowed to harden, and the plates were 
incubated for 3-5 h until plaques started to form. Hybond-C Extra membranes were marked 
with a ballpoint pen or pencil, and soaked in ~30 ml 10 mM IPTG solution. As soon as 
plaques began to appear, one soaked Hybond-C Extra membrane was placed on each plate, 
avoiding bubbles between the membrane and top agarose. The membranes were pad-dried 
on filter paper if necessary. The Hybond-C Extra membranes (now on the plates) were 
marked, using needles, with asymmetrically arranged holes through the membrane and 
agar. The plates were then incubated for 3-4 h, and placed at 4°C for overnight.   
3.17.17 Film exposure      
See above (3.17.14). 
3.17.18 Alignment of blots 
See above (3.17.15). 
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4 RESULTS 
 
4.1 Regulation of the gene encoding the intestinal bile acid 
transporter ASBT by the caudal-type homeobox proteins CDX1 
and CDX2 
 
4.1.1 Expression profiling of genes of interest in human intestinal cell lines 
To investigate the expression profiles of genes of interest in the intestinal cell lines, I 
analyzed the relative gene expression levels in human colon adenocarcinoma-derived cell 
lines: HT29, DLD1, Caco-2, T84, and LS174T. Despite the same tissue origin of these cell 
lines the mRNA expression levels of CDX1, CDX2, HNF-1α, GATA4, and ASBT varied 
considerably. When analyzing the expression levels of these genes, we found that HNF-1α 
levels appeared to correlate with ASBT, whereas CDX1 and CDX2 expression levels do 
not. Thus, we speculate that HNF-1α, but not CDXs, maintains the baseline ASBT 
expression level (Fig. 4.1). 
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Fig. 4.1 Endogenous mRNA expression levels in HT29, DLD1, Caco-2, T84, and LS174T cell 
lines. A, CDX1; B, CDX2; C, HNF-1α; D, GATA4; E, ASBT. All gene expression levels were 
relative to those of β-actin. 
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4.1.2 Modulation of endogenous ASBT mRNA expression levels by CDX knockdown 
or overexpression 
To investigate whether endogenous human ASBT mRNA levels were regulated by CDX1 
and CDX2, I performed knockdown experiments with pools of siRNAs specifically 
targeting CDXs. For this purpose, I chose the human colon cancer cell line T84, which 
endogenously expresses CDX1, CDX2, and ASBT, all at detectable levels. By targeting 
the endogenous CDX1 or CDX2 with specific siRNAs, ASBT mRNA expression was 
significantly decreased compared to that in control cells (Fig.  4.2A). Upon CDX1 siRNA 
treatment, there was an 80 % loss of endogenous CDX1 mRNA, and no decrease in the 
endogenous CDX2 mRNA level (Fig. 4.2B). Conversely, upon CDX2 siRNA treatment, 
there was a significant loss of endogenous CDX2 mRNA, but endogenous CDX1 mRNA 
expression level remained unchanged (Fig. 4.2C). The siRNA knockdowns thus worked in 
a gene-specific manner. In a converse approach, I transiently overexpressed CDX1 and 
CDX2 in human esophagus-derived OE19 cells. As shown in Fig. 4.2D, endogenous 
mRNA levels of ASBT were significantly increased upon exogenous expression of CDX1 
and CDX2 in the esophageal cell line. 
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Fig. 4.2 Modulation of endogenous ASBT mRNA expression levels by CDX1 and CDX2. A–C, 
ASBT mRNA expression levels were reduced upon knockdown of endogenous CDX1 and CDX2 
expression in T84 cells. Cells were transfected with control non-targeting siRNA, siCDX1, or 
siCDX2 at a final concentration of 50 nM twice at a 24 h interval, and harvested after 48 h. ASBT, 
CDX1 and CDX2 mRNA expression levels were normalized to those obtained for β-actin. A, 
Knockdown of CDX1 or CDX2 led to a significant decrease in ASBT mRNA expression. B, CDX1 
siRNAs significantly reduced CDX1, but not CDX2 expression. C, CDX1 siRNAs significantly 
reduced CDX1, but not CDX2 expression. D, Exogenous expression of CDX1 and CDX2 
significantly increased endogenous ASBT mRNA levels in human esophagus-derived OE19 cells. 
**P<0.01; ***P<0.001. 
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4.1.3 CDX1 and CDX2 transactivate the ASBT promoter  
To study further the possible direct role of CDX1 and CDX2 in the regulation of the ASBT 
promoter, I transiently transfected two human esophagus-derived cell lines and three 
human colon-derived cell lines with expression plasmids for human CDX1 and CDX2, 
together with the ASBT (-1688/+525; numbering relative to the transcriptional start site) 
promoter luciferase construct. Both CDXs increased ASBT promoter activity in two 
esophageal cell lines, OE19 (Fig. 4.3A) and Het-1A (Fig. 4.3B). Potent CDX-mediated 
activation of the ASBT promoter was also observed in intestinal T84 (Fig. 4.3C), Caco-2 
(Fig. 4.3D), and LS174T (Fig. 4.3E) cells. A comparative study with human, mouse and rat 
ASBT/Asbt promoter luciferase constructs transfected into Caco-2 and murine IEC-4.1 cells 
revealed an increased activity of the mouse Asbt promoter by both CDX1 and CDX2 in 
both cell lines, whereas the rat Asbt promoter was significantly activated by CDX1 and 
CDX2 in IEC-4.1 cells, but only by CDX2 in Caco-2 cells (Fig. 4.3F and G). 
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Fig. 4.3 CDX1 and CDX2 transactivate the human ASBT (A–E), and mouse (mAsbt; F and G) 
and rat (rAsbt; F and G) Asbt promoters. Two hundred nanograms of CDX1 or CDX2 
expression plasmids were transfected into OE19, Het-1A, T84, Caco-2 and LS174T cells, together 
with 400 ng of ASBT (-1688/+525) promoter luciferase construct. Reporter activities were 
measured 36 h later. A, OE19 cells; B, Het-1A cells; C, T84 cells; D, Caco-2 cells; E, LS174T 
cells; F, Caco-2 cells; G, IEC-4.1 cells. **P<0.01; ***P<0.001; ns, not significant. 
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4.1.4 In silico analysis of the ASBT promoter region 
I performed an in silico analysis of the proximal 850 base pairs of the human proximal 
promoter and 525 base pairs of the 5’-untranslated (UTR) ASBT gene region (NCBI 
Reference Sequence: NT_009952.14), to identify putative CDXREs. The consensus core 
motif for CDX DNA-binding is 5′-TTTAT/C-3′ or 5′-G/ATAAA-3′ [86]. We identified 12 
putative CDXREs within the proximal ASBT (-850/+525) promoter region by MatInspector 
software [204] and visual inspection (Fig. 4.4). 
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Fig. 4.4 Sequence of the proximal ASBT promoter region (-850/+525). The transcription start 
site is indicated by an arrow. The consensus motifs found in the nine predicted CDXREs are shown 
in bold. The location of the oligonucleotide primers used in ChIP assays are indicated with 
underlining arrows. The positions of the predicted promoter CDXREs are shown in bold. The 
location of the oligonucleotide primers used in ChIP assays are indicated with underlining arrows. 
The positions of the predicted CDXREs were as follows: CDXRE1 (-722/-717); CDXRE2 (-672/-
667); CDXRE3 (-621/-616); CDXRE4 (-583/-578); CDXRE5 (-541/-536); CDXRE6 (-480/-475); 
CDXRE7 (-424/-419); CDXRE8 (-337/-332); and CDXRE9 (-161/-156). We further found three 
putative CDXREs in the 5’-UTR region of the ASBT gene: CDXRE10 (+274/+278); CDXRE11 
(+303/+307); and CDXRE12 (+412/+426). 
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4.1.5  The region containing the predicted CDX binding sites mediates ASBT 
promoter activation 
To study whether the proximal promoter region containing the predicted CDXREs could 
mediate CDX-dependent activation, I used two ASBT promoter deletion constructs in 
transient transfection of Caco-2 cells. The construct ASBT (-830/+525), which contained 
all the predicted CDXREs, was potently activated by both CDX1 and CDX2, whereas the 
construct ASBT (-99/+525), lacking all nine predicted promoter CDXREs, exhibited 
significantly reduced activation (Fig. 4.5A). This effect was also observed in human EAC-
derived cell line OE19 (Fig. 4.5B). Although a similar trend was observed in another 
esophagus-derived cell line Het1A; the loss of activation upon deletion of the CDXREs 
was not statistically significant (Fig. 4.5C). The activation of the ASBT promoter by CDXs 
was not entirely abolished, suggesting that ther CDXREs located in the 5′-UTR of the 
ASBT gene may contribute to the effect. 
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Fig. 4.5 Region containing the predicted CDX binding sites mediates ASBT promoter 
activation. Two hundred nanograms of the CDX1 or CDX2 expression plasmids were transfected 
into cells, together with 400 ng of the ASBT (-830/+525) or ASBT (-99/+525) promoter luciferase 
construct. Reporter activities were measured 36 h later. A, T84 cells; B, OE19 cells; C, Het1A cells. 
*P<0.05; ***P<0.001. 
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4.1.6 Identification of the CDX binding sites that mediate ASBT promoter activation 
To study further which of the predicted CDXREs mediated CDX-dependent activation in 
the proximal promoter region, I created eight ASBT promoter constructs in which critical 
point mutations were introduced to the individual CDXREs by site-directed mutagenesis 
using the ASBT (-830/+525) promoter construct as a PCR template (Fig 4.6A). As neither 
CDX1 nor CDX2 were able to bind to the CDXRE1, CDXRE5, or CDXRE6 in vitro (see 
below), mutation constructs were not created for these binding sites. In transient 
transfections in Caco-2 cells, the construct ASBT (-830/+525), which contained all the 
predicted CDXREs, was potently activated by both CDX1 and CDX2, and the most 
significant loss was observed when mutations were introduced to CDXRE4 in the proximal 
promoter (Fig. 4.6B). In the case of CDXREs in the UTR, mutation of the binding site 
CDXRE12 showed the most pronounced reduction of CDX activation (Fig. 4.6C). 
However, no single CDXRE mutation could entirely abolish the activation in response to 
CDX, suggesting that more than one CDXRE mediate ASBT promoter activation.  
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Fig. 4.6 Identification of functional CDX binding sites that mediate human ASBT promoter 
activation. A, Schematic view of ASBT deletion constructs; the box with a number indicates that 
point mutations were introduced at the specific binding site by site-directed mutagenesis.  The short 
vertical line with arrow indicates transcription start site (TSS). B, Caco-2 cells were cotransfected 
with a reporter-linked ASBT promoter deletion construct -1688/+525, -830/+525, or -492/+525, or 
the -830/+515 construct containing mutations in either CDXRE2, CDXRE3, or CDXRE4 within the 
proximal promoter region. With each construct, either a CMV promoter-driven expression plasmid 
for CDX1, or an empty pcDNA3.1(+) vector (control) was cotransfected. C, Caco-2 cells were 
cotransfected with reporter-linked ASBT promoter construct -1688/+525, -830/+525, -492/+525, 
CDXRE 8, CDXRE 9, or CDXRE10–12 in the 5’ UTR region, as well as the promoterless reporter 
vector pGL3basic. With each construct, either a CMV promoter-driven expression plasmid for 
CDX1 and CDX2, or an empty pcDNA3.1(+) vector (control) was cotransfected. Relative 
luciferase activities obtained for pcDNA3.1(+)-transfected cells were set to 1, and the fold 
activities in other test conditions are shown relative to these. *P<0.05; ***P<0.001; ns, not 
significant. 
4.1.7 Synergistic activation of the ASBT proximal promoter by CDX1 and HNF1α  
In a known evolutionarily conserved mechanism, CDXs interact with the transcription 
factors HNF-1α and GATA4 in regulation of several intestine-specific genes. The 
following experiments investigated, whether CDX1 functionally interacts with the HNF-
1α and/or GATA4 factors in the context of ASBT promoter. As expected, CDX1 or HNF-
1α alone transactivated the promoter. When CDXs and HNF-1α were simultaneously 
overexpressed in cells, this led to ~100-fold activation, which greatly exceeded that 
induced by CDXs or HNF-1α alone or additively. It is interesting to note that transfection 
of cells with the GATA4 expression plasmid significantly reduced the synergism between 
CDX1 and HNF-1α (Fig 4.7). 
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Fig. 4.7 Cooperative transcriptional regulation by CDX1, HNF-1α , and GATA4 on the ASBT 
promoter. Two hundred nanograms of CDX1, HNF-1α, and/or GATA4 expression plasmids were 
transfected into cells. In relevant cases, the total amount of CMV promoter-containing DNA was 
adjusted by adding pcDNA3.1(+) construct, together with 400 ng ASBT (-1688/+525) promoter 
luciferase construct. Reporter activities were measured 36 h later. ***P<0.001. 
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4.1.8 Antibody specificity tests in EMSAs  
To confirm the specificity of CDX1 and CDX2 antibodies used in EMSA, I tested the 
cross-reactivity of the antibodies: CDX1 antibody with in vitro translated CDX2 proteins, 
and CDX2 antibody with in vitro translated CDX1 proteins (Fig. 4.8). Loss of DNA-
binding was observed when CDX1 antibody was added to the CDX1 protein mixture (lane 
2). By addition of either of the two CDX2 antibodies did not interfere with CDX1 protein 
binding to DNA (lanes 3 and 4). In a reciprocal manner, when adding CDX2 antibody to 
CDX2 protein binding reactions, CDX2 proteins were supershifted thus forming larger and 
slower migrating protein complexes (lanes 6 and 7), whereas adding CDX1 antibody did 
not alter or reduce CDX2 protein-probe complex formation  (lane 8). 
 
 
 
Fig. 4.8 CDX1 and CDX2 antibodies specifically recognize the respective proteins. EMSAs 
were carried out using in vitro translated CDX1 and CDX2 proteins. CDX consensus binding site 
from the human desmocollin 2 gene was used as a radiolabelled probe. The specificity of the 
complexes was confirmed by incubation with an anti-CDX1 antibody or two different anti-CDX2 
antibodies.  
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4.1.9 CDX1 and CDX2 bind to six of the nine predicted CDXREs on the ASBT 
promoter in vitro 
To study the potential in vitro interaction between CDX1 and CDX2 with their predicted 
binding motifs within the ASBT promoter, I performed EMSAs using nuclear extracts 
derived from LS174T cells, in which both CDX1 and CDX2 are endogenously expressed, 
using wild-type and mutant predicted CDXREs as radiolabeled probes. Two DNA-protein 
complexes were formed on the CDXREs 2, 3, 4, 7, 8, and 9, which were abolished by 
addition of either CDX1 (faster complex) or CDX2 (slower complex) antibodies (Fig. 
4.9A). Addition of unrelated antibodies raised against the nuclear receptor transcription 
factors PPARα or RXRα did not affect CDX–DNA complex formation. When mutations 
designed to interfere with CDX DNA-binding were introduced into the oligonucleotides 
and used as radioactively labelled probes, the formation of the two CDX-DNA complexes 
was abolished or strongly reduced. The other putative CDXREs within the proximal ASBT 
promoter (CDXREs 1, 5, and 6) predicted in silico failed to form specific complexes with 
CDXs in EMSAs (data not shown). To further confirm the specificity of CDX1 and CDX2 
binding to the CDXREs within the ASBT promoter, I performed EMSA competition 
experiments (Fig. 4.9B), using the CDX consensus binding site from the human 
desmocollin 2 gene as a radiolabelled probe, and increasing molar excesses of unlabelled 
competitor oligonucleotides harbouring the ASBT promoter CDXREs. The binding of 
recombinant in vitro translated CDXs to their consensus binding site was competed off in a 
dose-dependent manner, upon addition of competitor oligonucleotides containing each 
wild-type CDXRE of the ASBT promoter. Mutated CDX elements were incapable of, or 
significantly less efficient in, competing for CDX binding. These data indicate that CDXs 
are able to bind specifically to CDXREs in the proximal ASBT promoter sequence in vitro. 
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Fig. 4.9 CDX1 and CDX2 bound to six predicted CDXREs in vitro. EMSAs were carried out 
using nuclear extracts from LS174T cells. Oligonucleotides containing the six predicted wild-type 
or mutant CDXREs within the proximal ASBT promoter were radioactively labelled for use as 
probes. CDX1 and CDX2 complexes are indicated by black arrowheads (lanes 1, 7, 13, 19, 25, and 
31). The specificity of the complexes was confirmed by incubation with an anti-CDX1 (lanes 2, 8, 
14, 20, 26, and 32) or anti-CDX2 (lanes 3, 9, 15, 21, 27, and 33) antibody. To confirm the 
specificity of the protein-DNA complexes, as well as the anti-CDX antibodies used in supershifts, 
anti-PPARα (lanes 4, 10, 16, 22, 28, and 34) and anti-RXRα (5, 11, 17, 23, 29, and 35) antibodies 
were tested in parallel. The asterisks indicate the location of CDX2-probe complexes supershifted 
with antibodies. The anti-CDX1 antibody abolished the CDX1-probe complexes, rather than 
produced a defined supershift. The interaction between the radiolabelled probes and CDXs was 
abolished or strongly reduced by mutations to crucial bases within CDX binding sites (lanes 6, 12, 
18, 24, 30, and 36). The two EMSA image panels were derived from the same experiment and from 
film exposure times of equal length. B, Competition EMSAs were carried out using in vitro 
translated CDX1 and CDX2 proteins, both simultaneously added to the binding reactions. 
Unlabelled oligonucleotides containing the CDXREs from the human ASBT promoter were added 
in 10-, 50-, or 100-fold molar excess. The oligonucleotide containing the consensus CDXRE 
derived from the human desmocollin 2 promoter was used as the radioactively labelled probe. The 
two EMSA image panels were derived from the same experiment and from film exposure times of 
equal length. 
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4.1.10 CDX1 and CDX2 interact with the proximal ASBT promoter region within 
living cells 
To confirm the interaction between CDX1 and CDX2 with the ASBT promoter in living 
cells, ChIP assays were performed using nuclear proteins extracted from T84 cells in 
which CDX1, CDX2 and ASBT are all endogenously expressed. As shown in Fig. 4.10 
(upper panel), two different CDX1 and two CDX2 antibodies were efficient in 
precipitating the promoter region ASBT (-736/-154), whereas the nonspecific mouse IgG 
antibodies failed to precipitate the ASBT promoter region. As an additional specificity 
control, I amplified a 221 bp region from the first intron of the ASBT gene using the same 
ChIP samples as templates. None of the CDX antibodies was able to precipitate this 
intronic region of the ASBT gene (Fig. 4.10, lower panel). 
 
  
 
Fig. 4.10 CDX1 and CDX2 interact with the proximal, CDX-responsive, ASBT promoter 
region within living cells. ChIP assays were performed in T84 cells. Two different CDX1- and 
CDX2-specific antibodies, but not the negative control antibody (mouse IgG), were efficient in 
precipitating the promoter region ASBT (-736/-154) (upper panel). None of the antibodies could 
precipitate the intronic region located approximately eight kbps downstream of the transcriptional 
start site of the ASBT gene (lower panel). 
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4.1.11 Correlation analysis of CDX, ASBT, and HNF-1α  expression levels in human 
BE and ileal tissue 
To study whether CDXs or the known transactivator of the ASBT promoter, HNF-1α [150], 
are chief factors in maintaining the expression of ASBT mRNA in human BE tissue, I 
measured the expression of all four genes in RNA isolated from esophageal biopsies 
derived from BE patients. Tissue was obtained from 35 patients, and 20 expressed mRNAs 
of all genes of interest. ASBT mRNA levels were significantly correlated with those of 
CDX1 (Fig. 4.11A), CDX2 (Fig. 4.11B), and HNF-1α (Fig. 4.11C). I observed a strong and 
significant correlation between the mRNA expression levels of CDX1 and CDX2 (Fig. 
4.11D). In addition to the BE tissue, I also investigated the potential correlation between 
CDX, HNF-1α and ASBT expression levels in ileal tissue derived from 48 healthy subjects. 
ASBT mRNA levels were not significantly correlated with those of either CDX1 (Fig. 
4.11E) or CDX2 (Fig. 4.11F), although there was a significant correlation between ASBT 
and HNF-1α mRNA expression (Fig. 4.11G). Similar to the BE tissue, there was a 
significant correlation between mRNA expression levels of CDX1 and CDX2 in the 
healthy ileum (Fig. 4.11H). 
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Fig. 4.11 Correlation of CDX1 (A), CDX2 (B) and HNF-1α (C) mRNA expression levels with 
those of ASBT in BE biopsies from 20 subjects, using linear regression analysis. D, Correlation 
analysis of CDX1 and CDX2 mRNA levels with each other in BE tissue. R2 values and P values: A, 
R2=0.7789, P<0.0001; B, R2=0.7861, P<0.0001; C, R2=0.5513, P<0.0001; D, R2=0.7965, P<0.0001. 
β-Actin was used as a housekeeping gene for normalization in esophageal material. Correlation of 
CDX1 (E), CDX2 (F) and HNF-1α (G) mRNA expression levels with those of ASBT mRNA in 
ileal biopsies from 48 healthy subjects, using linear regression analysis. H, Correlation of CDX1 
and CDX2 mRNA levels in ileal tissue. R2 values and P values: E, R2 = 0.00000141, P=0.9936; F, 
R2=0.02726, P=0.2621; G, R2=0.1732, P=0.0033; H, R2=0.2019, P=0.0014. Villin was used as the 
housekeeping gene for normalization in ileal material. Logarithmically transformed values of 
CDX1, CDX2, HNF-1α, and ASBT mRNA levels were used. 
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4.1.12 Immunostaining for CDXs and ASBT proteins in formalin-fixed paraffin-
embedded (FFPE) blocks from BE tissues 
I attempted to localize CDXs and ASBT proteins in tissue sections from FFPE blocks 
derived from esophagus of BE patients. All tissue samples contained distinguishable BE 
features, namely goblet cells and columnar cells. Although no staining for ASBT was 
detected in the columnar cells, some was observed in goblet cells (Fig. 4.12A,B). Therefore, 
it seems possible that the human ASBT antibody available to us generated nonspecific 
staining, and optimized staining will be needed to validate this. I also observed specific 
nuclear staining for CDX2 as expected in tissue sections with columnar and goblet cells 
(Fig. 4.12C,D). However, none of the tissue sections could be stained with the CDX1 
antibody (Fig. 4.12E,F). 
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Fig. 4.12 Protein localization of human ASBT, CDX1, and CDX2 in tissue section from FFPE 
blocks of BE patients. A, B, Staining for the ASBT protein. C, D, Nuclear staining for the CDX2 
protein. E, F, Staining for the CDX1 protein. Antibodies used: ASBT antibody (Paul Dawson 
Laboratory, Wake Forest, USA), CDX2 antibody (Maixin MAB-0216, Xiamen, China), and CDX1 
antibody (AP6130a; Abgent, San Diego, CA, USA). 
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4.2 Regulation of the gene encoding the intestinal bile acid 
transporter OSTα /β   by the caudal-type homeobox proteins 
CDX1 and CDX2. 
 
4.2.1 In silico promoter analysis of the OSTα/β gene promoters 
As shown previously, CDXs can regulate the ASBT promoter. Therefore it was of interest 
to investigate whether CDXs play a role in promoter regulation of the genes encoding 
intestinal BA export proteins, namely OSTα/β. First, I analyzed the proximal 927 bp of the 
human OSTα promoter (NCBI Reference Sequence: NT_029928) and human 1453 bp 
OSTβ promoter (NCBI Reference Sequence: NW_925884), to identify putative CDXREs. 
The consensus core motif for CDX DNA binding is 5′-TTTAT/C-3′ or 5′-G/ATAAA-3′ [86]. 
We identified two putative CDXREs within the proximal OSTα (-927/+1) and six in the 
OSTβ (-1453/+1) promoter regions by visual inspection (Fig. 4.13 A,B).  
 
A 
    ctctccacaccccacagctttctgtctgacctggtttcttagcctctctggacctcagcc 
 
    tccttatctgtaaaatgggaataaggatactacttcccttgtaacgcggtggtaaagttt 
                                                  CDXRE2 
    aaataagctaaggaacacactgcatgtcctgcgggccctggcacaccagacatgctgaca 
 
    gacgctggctgctttcatcagctatgcaaccaaattctaaggggcccttcgtatgtgtca 
 
    ggctgcgtgccaggaacctagaggtaccaccgtaccacagtacaagatgctgtgtctggc 
 
    ttcgaagagatttcagtctatgtggagagagagaaaagggaagctatcagccaataaaat 
                                                       CDXRE1 
C  gtttgcaagcctgtaattcagcaggttttcaagacctgtcaaatgcccagcaatctcac 
 
    tctgcaactctgcctcttaaatacagcatcttccggcccagcgtgggggtggctaagccc 
 
    atcatccagatgtgatgaactggggtctgggaaacccacaccggcctcatctggcttttc 
 
    cagcctgtcctcccttccacacatcaggctgacagcaccaaacacggccgaggcctcagc 
 
    cctgagtctccccgctgcagagtgcccaagcctgagttccagcaggttcttcaggggccg 
 
    ctgaccagggaacactgcggtgaggagcgaggacttcgtccccaccccggcccagggcag 
 
    gggcttcgtggtgagcccaccccaccccagaaggctcctggaagggcagggcagactggc 
 
    agcaaaatcctataggatgggccgggccagaggcaaggggtggccaaaggcacctgtcca 
‐317 
‐439 
‐561 
‐500 
‐683 
‐622 
‐256 
‐195 
‐134 
‐378 
‐866 
‐927 
‐744 
‐805 
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   agaggtgggagggaccacacctgggggcagggacgagtcaggcacagggaactccgccag 
 
   cctagaggatcaaattcctccggggtgaactctgagatagaaagttggcccgggaagctc 
                                      TSS
 
B 
 
cgatcctccctgtacactttttttcttggtgccctatggcatgttttataattgatctgt 
                                  CDXRE6       
tcaaaacacttctcttgttttattttagttacgtttatctccattcctactcccttcctc 
           CDXRE5       
ctcctccccaagacacagcttaatgtgtttaatgcgtgtccttttaaaaaaatgtgttat 
 
tgggtcaggcgcggtggctcactcctgtaatcccagtactttgggaggccaaggcgggtg 
 
gatcacctgaggtcaagagttcgagaccagcctggccaacatggtgaaaccccatctcta 
 
ctaaaaatacaaaaattagtggggcggtagtgacatgcgcctgtaattccagctacttag 
 
gaggctgagacaggagaatcgcttgaacctgggaggcggaggttgcagtgagcagagatc 
 
gtgccactgcactccagcctgggcgacagagtgagactccgtctcaaaaaaaaaaaaaaa 
 
aaagcgaaataacttaacaattttaatattggcctgaataatatatgttgtcaaaattaa 
 
ttttacctatttctttttgttttgtaaagtatggatgctagaaaattttatattaagtag 
         CDXRE4                CDXRE3   
taataatgcagttagtacaagaagacgtcaaaatgtctgactgttttgagattgactgag 
 
gttcagtttattattaatagttgggatggaaataggcctacacgaagtaagggatttatc 
                                                      CDXRE2  
cagagagcatggattcaagttcttcccttgcaaataacagaaaccaattctgctaacttg 
 
tccaaaaaaaaaaaaaaaagaaaaaaaaagctctcggggtcggggcagggggtgccctct 
 
cagcatcaggagccggcagctgcctttccctccggcacttttcccttttctcctctctgt 
 
gtcgtaggcgtgccaatccccaggagagaggcgtgataggcccagcctttgacatgtggg 
 
gaaacacaggcctgtgattggctaccgcatgacacccaagggacaagttgctatggcaac 
 
gcgtgggcgcgctgtgggctcgtagaagccaggtgcggacgctgaacaggcaggcgaaga 
 
cccgagatgtcctttgcaagggtcccagaactcgccagtggctcagtcctcctcactccc 
 
agaacagtgctcctccacacatgcgatggcttttaataaatatttgagtcactcccactt 
                CDXRE1       
ccagtctctgcccctccaggctccacgtgctcctgggttcgttcgggtcgtttttgtccc 
 
ataactttgggccagaggagatctggatttgggcacagagggagatcaaactcgggtggg 
 
atatccagtcatgctgtctgctttgtttccaggggtcttcacggcttctctgcccagggg 
                                         TSS 
ccagaaccgaggaggccaggagggctgctggggctaaggggtctaaggacctcgttgcac 
‐12 
‐73 
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‐477 
‐599 
‐538 
‐721 
‐660 
‐294 
‐233 
‐172 
‐111 
‐416 
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Fig 4.13 In silico analysis of the OSTα /β  promoter regions. A, The sequence of the proximal 
OSTα promoter region (-927/+48). The transcription start site is indicated by “TSS”. Two predicted 
CDXREs were found, and they are shown in bold. The positions of the predicted CDXREs were as 
follows: CDXRE1 (-568/-564) and CDXRE2 (-814/-810). B, Sequence of the proximal OSTβ 
promoter region (-1435/+9). The transcription start site is indicated by “TSS”. The consensus 
motifs found in the six predicted CDXREs are shown in bold. The positions of the predicted 
CDXREs were as follows: CDXRE1 (-258/-254), CDXRE2 (-727/-723), CDXRE3 (-981/-977), 
CDXRE4 (-899/-903), CDXRE5 (-1357/-1353), and CDXRE6 (-1408/-1404). 
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4.2.2 CDX1 and CDX2 modulate endogenous OSTα/β   at the mRNA level 
Specifically targeted knocking down of endogenous CDX1 and CDX2 expression levels in 
T84 cells, in which both CDXs and OSTα/β are endogenously expressed, resulted in 
significantly reduced endogenous OSTα mRNA expression (Fig. 4.14A). Double 
knockdown of CDX1 and CDX2 did not significantly reduce the OSTα expression level, 
 whereas knocking down CDX1 and CDX2 both individually and in combination reduced 
the OSTβ mRNA levels (Fig. 4.14B). This suggested that CDXs regulate OSTα/β 
expression at the transcriptional level. 
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Fig. 4.14 Modulation of endogenous OSTα /β  mRNA expression levels by CDX1 and CDX2. A, 
OSTα mRNA expression was reduced upon knockdown of endogenous CDX1 and CDX2 
expression in T84 cells in comparison to control siRNA-transfected cells. B, OSTβ mRNA 
expression was reduced upon knockdown of endogenous CDX1 and CDX2 expression in T84 cells 
in comparison to control siRNA-transfected cells. Cells were transfected with control non-targeting 
siRNA, siCDX1, or siCDX2 at a final concentration of 50 nM, twice at a 24-h interval, and 
harvested after 48 h. OSTα, OSTβ, CDX1, and CDX2 mRNA expression was normalized to that 
obtained for β-actin. *, P<0.05; **, P<0.01; ***, P<0.001; ns, not significant.  
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4.2.3 CDX1 and CDX2 regulate OSTα/β promoters in a cell line-dependent manner 
In Caco-2 cells, both CDX1 and CDX2 transactivated the OSTα promoter, but CDXs had 
no effect on the OST-β promoter (Fig. 4.15A). However, CDX2, but not CDX1, 
transactivated the OSTα/β promoters in LS174T cells (Fig. 4.15B). Similarly to Caco-2 
cells, in DLD1 cells both CDX1 and CDX2 transactivated the OSTα promoter, but not the 
OSTβ promoter, despite several putative binding sites being found on the latter promoter 
region (Fig. 4.15C).   
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Fig. 4.15 CDX1 and CDX2 transactivate the human OSTα  and OSTβ   promoters in a cell 
line-dependent manner. Two hundred nanograms of CDX1 or CDX2 expression plasmids were 
transfected into Caco-2 (A), LS174T (B), and DLD1 (C) cells, together with 400 ng of OSTα (-
1457/+161) or OSTβ (-4748/+29) promoter luciferase constructs. Reporter activities were measured 
36 h later. Transfected OSTα/β promoters are indicated on the top of each graph. **, P<0.01; ***, 
P<0.001; ns, not significant. 
 
4.2.4 Correlation analysis of CDX and OSTα/β   expression levels in human BE 
tissue 
To study whether CDXs are chief factors in maintaining the expression of OSTα/β mRNA 
in human BE tissue, I measured their expression in RNA isolated from esophageal biopsies 
derived from BE patients. Tissue was obtained from 45 patients who expressed mRNAs of 
all four genes of interest. OSTα/β mRNA levels significantly correlated with those of 
CDX1 (Fig. 4.16A,B) and CDX2 expression levels only correlate significantly with 
OSTβ, not OSTα, although even in the latter case there is a clear tendency (Fig. 4.16C,D). 
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Fig. 4.16 Correlation of CDX1 versus OSTα  (A), CDX1 versus OSTβ  (B), CDX2 versus OSTα  
(C), and CDX2 versus OSTβ  (D) mRNA expression levels in BE biopsies from 45 patients, 
using linear regression analysis. R2 values and P values: A, R2=0.3128, P<0.0001; B, R2=0.8585, 
P<0.0001; C, R2=0.05998, P<0. 0.0832; D, R2=0.6185, P<0.0001. β-actin was used as a 
housekeeping gene for normalization in esophageal material. Logarithmically transformed values 
of CDX1, CDX2, OSTα, and OSTβ mRNA levels were used. 
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4.3 FW SCREENING 
4.3.1 Quality control of long-distance PCR amplification 
Construction of the cDNA library to be employed in the FW screening for novel interactors 
of CDXs was performed by a PCR-based method. To evaluate the size distribution, yield 
and quality of the library, a sample of 5 µl from the library was run in an agarose gel.  
 
 
 
Figure 4.17 Long-distance PCR to assess the quality of cDNA library construction. Upon 
completion of long-distance PCR, a 5 µl sample of the PCR product was analyzed alongside DNA 
Molecular Weight Marker VII (Roche), on a 1.1% agarose/ethidium bromide gel. Double-stranded 
cDNA should appear as a 0.1-4 kbp smear on the gel. 
4.3.2 Determination of the number of pfu of the unamplified cDNA library  
As shown in the calculation, characterization of the library revealed it to be of high quality. 
The current unamplified library contained ~4.5×106
 
independent clones, whereas a typical 
unamplified cDNA library has ~106
 
independent clones. 
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Ratio pfu/ml 
1: 2             120x16=1920x2x03=3.84x106 pfu/ml 
1:5             164x6=984x5x103=4.92x106    pfu/ ml 
1:10           76x4=304x10x103=3.04x106  pfu/ ml 
1:20          77+50+66+70=263x20x103= 5.26x106 pfu/ ml 
1:50          27x4=108x 50x103=5.4x106 pfu/ ml 
 Average = 4.5×106 pfu/ ml 
 
4.3.3 Determination of the number of pfu of the amplified cDNA library  
As shown in the calculation, after amplification of the unamplified library, it was expanded  
to ~35-fold of the original library.  
 
 
 
4.3.4 Determination of the percentage of recombinant clones 
Three blue plaques out of total of 920 were found on the plate; therefore, the percentage of 
recombination, and insert-containing clones, was (920-3)/920 = 99.6%. 
 
 
 
 
Ratio pfu/ml 
Plate 1:   74x104x103/ 5= 1.48x 108 pfu/mL 
Plate 2:  150x104x103/ 10= 1.5x108 pfu/mL 
Plate 3:   97x 4 quarters=388x104x103 =1.94 x108 pfu/mL 
Plate 4:  Control no plaque 
 Average = 1.6×108 pfu/mL 
RESULTS  89   
 
4.3.5 In vitro translation of pTNT-CDX1 and pTNT-CDX2 
In vitro translation of CDX1 was first carried out using the T7 promoter-containing 
original pcDNA3.1(+)-CDX1 vectors, no specific recombinant proteins of adequate quality 
or expected molecular weight could generated (Fig. 4.18A). The coding sequences of 
CDX1 and CDX2 were then subcloned into the pTNT vector bearing features that 
enhanced protein translation, namely the 5′-UTR leader sequence of the β-globin gene and 
a synthetic poly (A) tail, that enhance the transcriptional and translational efficiency. The 
proteins were translated using rabbit reticulocyte lysate and wheat germ extracts, that both 
contains necessary component of the protein translation machinery. In terms of translation 
efficiency and quality of the CDX1 and CDX2 protein product, no major differences were 
observed between the two systems. Reticulocyte lysate system was selected for the actual 
experiment in FW screening (Fig. 4.18B). 
 
A 
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B 
 
 
Fig. 4.18 Comparison of in vitro translation of CDX1 and CDX2 proteins using TNT coupled 
reticulocyte lysate systems and TNT coupled wheat germ extract system. A, Lane 1&2:  The 
pcDNA3.1(+)-CDX1 plasmid used as the template before purification by the Microcon centrifugal 
filtration units; Lane 3&4: CDX1 proteins after purification by the Microcon units with a molecular 
weight cut-off of 3 kDa; Lane 5&6: CDX1 proteins after purification by the Microcon units with a 
molecular weight cut-off of 10 kDa. B, Lanes 1: The pTNT-CDX1 plasmid used as the template for 
the in vitro translation reactions. The CDX1 protein was expected to migrate at 28 kDa. Lanes 2: 
The pTNT-CDX2 plasmid used as the template for the in vitro translation reactions. The CDX2 
protein was expected at to migrate at 33 kDa; Lanes E: The pTNT vector without an insert used as 
the template for the in vitro translation reactions. 
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4.3.6 Purification of in vitro translated CDX1 and CDX2 proteins 
The translated proteins were purified with a Microcon centrifugal filtration units to remove 
any molecules smaller than 3 or 10 kDa by centrifugation at speed of 14,000 rpm. As can 
be seen from Fig 4.19, the excess 35S-Met and 35S-Cys were efficiently removed upon the 
purification step. Ten kDa Microcon units were selected for the actual purification process 
in FW screening. 
 
 
 
Fig. 4.19 Purification of in vitro translated CDXs proteins with Microcon centrifugal filter 
units. Comparison of unpurified samples, samples purified using 3 kDa pore Microcon units, and 
samples purified using 10 kDa pore Microcon units. R1 = rabbit reticulocyte lysates synthesizing 
CDX1; R2 = Rabbit reticulocyte lysates synthesizing CDX2; W1 = Wheat germ extracts 
synthesizing CDX1; W2 = Wheat germ extracts synthesizing CDX2. 
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4.3.7 Far western screening 
We next performed the primary FW screening of 1.7×106
 
clones for each CDX protein. 
After the secondary screening, for the positive clones, the λTriplEx recombinant phages 
were converted to plasmids via excision and circularization. The plasmids were released by 
Cre recombinase-mediated recombination at loxP sites. Excision of the insert-containing 
plasmid occurred automatically, when recombinant phages were transduced into an E. coli 
host BM25.8 expressing the Cre recombinase. Conversion was performed on individual 
positive plaques selected from the secondary screening plate. Excised plasmids were then 
propagated stably in a recombinase-deficient E. coli strain. Screening of a small intestine 
and colon cDNA library (1.7×106
 
clones) using radioactive protein probes corresponding to 
the complete coding region of the human transcription factors CDX1 and CDX2 resulted in 
identification of 15 and 6 positive plaques in the primary screen, respectively. These were 
selected and subjected to two consecutive additional rounds of plaque purification. 
Following conversion of 42 plaque-purified clones from λTriplEx to pTriplEx, the insert 
sizes were determined by restriction analysis of the plasmid DNAs. The sequences of the 
inserts were identified by DNA sequencing, using oligonucleotide primers flanking the 
insert cloning site in pTriplEx. cDNAs listed in Table 4.1 encoded possible CDX1 
interaction partners, and those in Table 4.2 possible CDX2 interaction partners.  
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Table 4.1 List of putative CDX1 interaction partners. 
Clone 
number 
Reference sequence Encoded/predicted protein Known/proposed protein functions 
15A1 
 
ref|NT_011525.7| 
Bromodomain containing 
protein 1 
Component of the MOZ/MORF complex which has a histone H3 
acetyltransferase activity. 
15B1 ref|NM_001037165.1| Forkhead box K1 
Transcriptional regulator that binds to the upstream enhancer region 
(CCAC box) of myoglobin gene. Has a role in myogenic differentiation 
and in remodeling processes of adult muscles that occur in response to 
physiological stimuli 
16A1 ref|NM_018302.2| 
Chromosome 4 open reading 
frame 19 
N/A 
16B1 ref|NM_022463.3| nucleoredoxin 
Regulate the Wnt/β-catenin pathway, which regulates cell fate and 
early development. 
17A1 ref|NR_003680.1| 
ribosomal protein L13A 
pseudogene 
Ribosomal protein. 
17B1 ref|NM_002473.3| MYH9 Myosin, heavy chain 9, non-muscle. 
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18A1 ref|NM_018464.2| CISD1 
CDGSH iron sulphur domain 1. Plays a key role in regulating maximal 
capacity for electron transport 
and oxidative phosphorylation. May be involved in 
Fe-S cluster shuttling and/or in redox reactions. 
18B1 ref|NM_080748.2| C20orf52 Homo sapiens chromosome 20 open reading frame 52. 
19A1 ref|NM_020729.1| ODF2L Homo sapiens outer dense fiber of sperm tails 2-like. 
19B1 
ref|NT_009952.14|Hs1
3_10109 
Homo sapiens chromosome 13 
genomic contig, reference 
assembly. 
N/A 
20A1 ref|NM_001012.1| RPS8 Homo sapiens ribosomal protein S8. 
 
20B1 
No significant 
similarity found 
No significant similarity found. N/A 
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Table 4.2  List of putative CDX2 interaction partners. 
 
Clone 
number 
 
Reference sequence 
Encoded/predicted protein Known/proposed protein functions 
1 ref|NW_001842393.1|HsX_WGA1354_36  
 Homo sapiens chromosome X genomic 
contig, alternate assembly . 
 
2 ref|NW_001838967.1|Hs5_WGA360_36  
 Homo sapiens chromosome 5 genomic contig, 
alternate assembly.  
 
3 ref|NM_006565.2 
Homo sapiens CCCTC-binding factor (zinc 
finger protein) (CTCF), 
11 Zinc finger protein 
4 No significant similarity found.   
5 ref|NT_022184.14|Hs2_22340  
Homo sapiens chromosome 2 genomic contig, 
reference assembly. 
Mitochondrial trifunctional protein, 
alpha subunit precursor. 
6 ref|NW_001838877.2|Hs3_WGA270_36  
 Homo sapiens chromosome 3 genomic contig, 
alternate assembly.  
Hypothetical protein. 
7 ref|NW_001838967.1|Hs5_WGA360_36  
 Homo sapiens chromosome 5 genomic contig, 
alternate assembly.  
 Heterogeneous nuclear 
ribonucleoprotein H1 
8 ref|NM_000690.2 
Homo sapiens aldehyde dehydrogenase 2 
family (mitochondrial) (ALDH2), nuclear gene 
encoding mitochondrial protein, mRNA.  
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9 ref|NW_001842393.1|HsX_WGA1354_36  
 Homo sapiens chromosome X genomic 
contig, alternate assembly . 
Hypothetical protein. 
10 ref|NT_005403.16|Hs2_5560  
Homo sapiens chromosome 2 genomic contig, 
reference assembly. 
 Glutaminase. 
11 ref|NW_001842393.1|HsX_WGA1354_36  
Homo sapiens chromosome X genomic contig, 
alternate assembly.  
Hypothetical protein. 
12 ref|NW_001842393.1|HsX_WGA1354_36  
Homo sapiens chromosome X genomic contig, 
alternate assembly.  
Hypothetical protein. 
13 No significant similarity found.   
 
14 
 
ref|NW_001842393.1|HsX_WGA1354_36 
Homo sapiens chromosome X genomic contig, 
alternate assembly. 
Hypothetical protein. 
15 ref|NW_001842393.1|HsX_WGA1354_36  
Homo sapiens chromosome X genomic contig, 
alternate assembly.  
Hypothetical protein 
16 No significant similarity found. N/A N/A 
17 No significant similarity found. N/A N/A 
18 No significant similarity found. N/A N/A 
19 ref|NM_016426.4|   GTSE1 
Homo sapiens G-2 and S-phase 
expressed 1 
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20 No significant similarity found. N/A N/A 
21 ref|NM_006360.3 
Homo sapiens eukaryotic translation initiation 
factor 3, subunit. 
Eukaryotic translation initiation factor 
3, subunit M. 
22 ref|NM_005756.2 GPR64, transcript variant 4 
Homo sapiens G protein-coupled 
receptor 64 
23 ref|NW_001838967.1|Hs5_WGA360_36  H1 
Heterogeneous nuclear 
ribonucleoprotein 
24 ref|NT_008470.18|Hs9_8627  
Homo sapiens chromosome 9 genomic contig, 
reference assembly 
    
25 ref|NT_008470.18|Hs9_8627 
mitogen-activated protein kinase associated 
protein 1  
 
26 No significant similarity found. N/A N/A 
27 No significant similarity found. N/A N/A 
28 ref|NM_001042446.1|  CAST Homo sapiens calpastatin 
29 ref|NW_001838967.1|Hs5_WGA360_36  H1 
Heterogeneous nuclear 
ribonucleoprotein 
30 ref|NM_005756.2|  GPR64 
Homo sapiens G protein-coupled 
receptor 64 
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5 DISCUSSION 
 
5.1  Regulation of the gene encoding ASBT by CDX1 and CDX2 
Intestinal BA transporters are membrane proteins that are important in regulating the influx 
and efflux of BA. They are essential components of the enterohepatic circulation of BAs and 
of cholesterol homeostasis. It is therefore of physiological relevance to study the molecular 
regulatory mechanisms of the expression of these membrane transporters.  
 
I demonstrated in human intestine- and esophagus-derived cell lines that the human ASBT 
promoter is a direct target for transcriptional activation by the transcription factors CDX1 and 
CDX2. Knockdown of endogenous CDX1 and CDX2 with siRNAs resulted in reduced 
endogenous ASBT mRNA expression level (Fig. 4.2). Consistent with this, exogenous 
expression of CDXs resulted in increased ASBT promoter activity in luciferase reporter assays 
(Fig. 4.3A-C). The CDX-mediated activation was conserved in the mouse and rat Asbt 
promoters (Fig. 4.3D,E), and consistent with this, preliminary in silico analysis revealed 
several putative CDXREs in both rodent Asbt promoters (data not shown), even though their 
overall homology with the human ASBT promoter was low. The level of activation of the 
rodent Asbt promoters appeared lower than for the human ASBT promoter. However, one 
limitation of the experimental setup was that human CDX expression constructs were used, 
and these may have had different coactivator requirements from their rodent counterparts. It 
will be interesting to study whether the intestinal Asbt expression and consequently BA 
absorption is reduced in Cdx mutant mice, although it should be noted that complete 
Cdx1/Cdx2-null mice cannot be analyzed for this purpose, because they are not viable until 
birth. It is interesting to note that the CDX-mediated activation was conserved in the mouse 
and rat Asbt promoters. Consistent with this, preliminary in silico analysis revealed several 
putative CDXREs in both rodent Asbt promoters (data not shown).  
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I identified several putative CDXREs within the proximal human ASBT promoter in in silico 
analysis (Fig. 4.4), and deletion of the promoter region harbouring these motifs significantly 
reduced transactivation by CDXs (Fig. 4.5). Of the seven promoter constructs containing 
individually mutated CDXREs all showed reduction in CDX-mediated activation compared to 
the control vector, although disruption of any single element did not lead to complete 
abolition of ASBT promoter activation (Fig. 4.6). It is of advantage for a given factor or 
particular gene promoters to have more than one response element: 1) this may allow step-
wise activation depending on the occupancy of the response elements on the gene promoter, 
2) this may compensate for loss of a binding site caused by DNA damage, or to prevent the 
effects caused by a polymorphism occurring within a single response element. Six of these 
predicted CDXREs could bind both recombinant and endogenous nuclear CDX proteins in 
vitro (Fig. 4.8 and 4.9). The region containing these six novel CDX binding sites also 
interacted with both CDX1 and CDX2 within living cells, as shown in ChIP assays (Fig. 4.10). 
In healthy human ileal tissue, there was no correlation between mRNA expression of the 
CDX transcription factors and ASBT (Fig. 4.11E,F), indicating that CDXs may not be crucial 
for maintaining the baseline ASBT expression level in normal human ileum, but may rather 
be important in ASBT promoter regulation in different tissues in response to specific 
signalling pathways, or in certain pathological conditions, such as BE. A correlation has been 
previously reported between ASBT and CDX2 in ileal tissue of patients suffering from 
chronic diarrhea [205]. In contrast to CDXs, the mRNA levels of HNF-1α were significantly 
correlated with ASBT mRNA expression levels in the ileum (Fig. 4.11G), confirming that 
HNF-1α contributes to the baseline expression of ASBT. This is consistent with reports that 
HNF-1α-null mice have severely reduced Asbt expression, and that ileal HNF-1α protein 
levels correlate with ASBT mRNA levels in humans [206]. Ileal CDX1 and CDX2 expression 
levels were also significantly correlated with each other (Fig. 4.11H), supporting the prior 
suggestion that they mutually regulate of one another expression [106].  
 
CDX1 and CDX2 play important roles not only in early gastrointestinal development, but also 
in gastrointestinal diseases in adult humans. Their ectopic overexpression in esophageal and 
stomach metaplasia suggests that they play a role in the pathogenesis of these diseases [207]. 
Alternatively, CDX expression could be the consequence rather than the cause of metaplasia. 
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Given the elevated and ectopic expression of both CDXs and ASBT in BE, we studied 
whether CDXs acted as regulators of the ASBT promoter. In human esophageal and intestine-
derived cell lines, the human ASBT promoter was a direct target for transcriptional activation 
by the transcription factors CDX1 and CDX2. My results add the intestinal BA transporter, 
ASBT, to the list of genes regulated by CDXs. Other intestinal transporters regulated by CDXs 
include peptide transporter 1 (PEPT1) [103] and sodium-coupled monocarboxylate 
transporter (SMCT)-1 [104]. Furthermore, the present research adds another component to the 
already known complexity of transcriptional regulation of ASBT gene expression.  
 
Cooperative synergism between CDX1 and HNF-1α in the activation of the ASBT promoter is 
shown in Fig 4.7. In this context, it is interesting to note that it has been previously proposed 
that HNF-1α and CDX2 cooperate with each other in the regulation of the intestinal genes 
sucrase isomaltase [96] and calbindin-D9k [208]. It is currently not known whether the CDXs 
interact with the previously identified regulators of the ASBT promoter, such as GR [44], 
HNF-1α, and PPARα [45]. 
 
The correlation between the mRNA expression levels of CDXs and ASBT was confirmed in 
BE biopsy material. The role of BA in the molecular pathogenesis of esophageal metaplasia 
remains somewhat unclear, although BAs has been shown to augment directly expression of 
CDX1 [106] and CDX2 [162]. It may thus be that secondary to gastrointestinal reflux, the 
BAs that enter the esophagus lead to elevated ASBT expression via induction of their 
transactivator CDXs. Excess level of BAs are toxic and have been shown to be carcinogenic 
to the gastrointestinal tract [209], and liver [210-212], and BAs are the major component of 
the duodenal juice, which can cause severe esophageal mucosal damage [145]. Dvorak et al. 
have demonstrated that ASBT, IBABP and MRP3 are elevated in BE and decreased in EAC, 
at both the mRNA and protein levels. It has been proposed that BA transporter expression in 
gastrointestinal metaplasia of the esophagus serves as a protective mechanism by the host to 
remove excess BAs secondary to chronic biliary reflux.  
 
As in healthy human ileal tissue, CDX expression did not correlate with ASBT expression, 
this regulatory mechanism may be more relevant in BE than in healthy ileum. Gene 
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expression levels are not maintained by a single transcription factor. As mentioned in the 
introduction, human ASBT gene expression is known to be transcriptionally regulated by 
multiple factors. Correlation has been previously reported between ASBT and CDX2 in ileal 
tissue of patients suffering from chronic diarrhea [205].  
5.2 Regulation of the gene encoding OSTα /β   by CDX1 and CDX2 
The mRNA and protein levels of OSTα/β are closely correlated, suggesting that tight 
transcriptional co-regulation of the two genes is essential for functional protein complex 
production [85]. It is therefore of physiological relevance to understand the transcriptional 
activators or repressors that modulate OSTα/β expression. BAs induce OSTα/β promoters via 
acting as ligands for FXR [80]. Two functional FXR response elements were found on the 
OSTα promoter and one on the OSTβ promoter [18]. I propose OSTα/β are other novel target 
genes for CDX1 and CDX2. 
In the second section of the presented work, in silico promoter analyses provided support for 
the hypothesis that CDXs transcriptionally regulate the OST genes. Two CDXREs were 
identified in the OSTα proximal promoter region and six in the OSTβ proximal promoter 
region (Fig 4.13A&B). it was shown that, by knocking down endogenous CDX1 and CDX2 
in T84 cells, the endogenous levels of OSTα and OSTβ were notably decreased in 
comparison to control siRNA (Fig. 4.14). This suggests that the OSTα/β  genes may be 
transcriptional targets of CDXs. It was also demonstrated that CDX1 and CDX2 
transactivated the OSTα, but not OSTβ, promoter in Caco-2 and DLD1 cells (Fig. 4.15A,C). 
In the LS174T cell line, CDX2 but not CDX1 transactivated the OSTα/β promoters (Fig. 
4.15B). Overexpressing CDXs, despite the abundance of putative CDXREs located within the 
OSTβ promoter, did not elevate the OSTβ expression levels. The apparent contradiction in 
promoter activation could be explained as there might have been missing cofactors in the 
transcriptional machinery complex within specific cell lines. 
 
CDX1/2 mRNA levels correlate with OSTα/β  level in BE tissue biopsies (Fig 4.16).  Taken 
together, it is interesting to note that both ASBT and OSTα/β genes thus appear coordinately 
regulated by the intestinal transcription factors CDX1 and CDX2. I have described here for 
DISCUSSION  102   
 
the first time the expression of BA efflux transporters OSTα/β in the BE tissue. I speculate 
that in the microenvironment of BE, ASBT react first to the exposure of BAs, whereas 
OSTα/β on the opposite of the membrane help to remove excess intracellular toxic BAs, 
thereby reducing cellular stress. An adaptive response to elevation of OST has been 
previously described in cholestatic liver disease [213].  
Further confirmations are needed before any firm conclusion can be drawn. EMSAs using 
nuclear extracts from intestinal cells, together with appropriate antibody supershifts, and the 
putative CDXREs as EMSA probes, as well as ChIP experiments, are required to confirm the 
in vitro and in vivo interactions between CDX factors and the OST promoter regions. 
5.3 Far western screening 
Identification of protein partners is an important way to understand protein function. In the 
work described above, a high-quality cDNA library was constructed from commercially 
available human small intestine and colon mRNA that represented a broad spectrum of 
proteins in these tissues. The construction involved a SMART technique, which enhanced the 
full-length cDNA, preserving the 5′ end of the sequence. The cDNA library was subsequently 
propagated in the lambda phage and the radiolabelled in vitro translated protein products were 
used as probes for FW screening. After primary and secondary screening procedures, I 
identified potentially positive phage clones, which were isolated from plaques and 
subsequently sequenced and analyzed with the BLAST software 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Several different genes were identified, including 
GPCRs, myosin, ribosomal protein 8, and nucleoredoxin. I found two particularly promising 
CDX interaction partners that are discussed in more detail below. 
 
The protein “Bromodomain-containing 1” (BRD1) has a highly conserved bromodomain that 
contains 220 amino acids. A bromodomain consists of four α-helices, and is present in nearly 
all nuclear histone acetyltransferases (HATs), which are involved in the chromatin structure 
regulation and gene expression [214]. Bromodomains recognize acetate lysine-containing 
peptides, components of the SWI/SNF chromatin remodeling complex. Bromodomain-
containing ptoteins are epigenetic remodelling factors. CDX2 has been previously shown to 
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interact directly with the BRM-type SWI/SNF chromatin remodelling complex, and these two 
proteins cooperatively regulate villin expression in intestinal cells [215].  
 
CTCF is a CCCTC motif-binding transcription factor that was originally identified as a factor 
that binds to the CT-rich region of the chicken c-myc gene with 11 highly conserved zinc 
finger DNA-binding domains. Given different cellular settings, CTCF can act either as a 
transcriptional activator by binding to a HAT-containing complex or function as a 
transcription repressor by binding to a histone-deacetylase (HDAC) complex [216]. We 
propose that CTCF may interact with either CDX1 or CDX2, thus regulating their 
transcriptional activity.   
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6 CONCLUSIONS AND FUTURE 
PERSPECTIVES 
I conclude that CDX1 and CDX2 can regulate the ASBT gene at the transcriptional level. 
Evidence for this regulation and elucidation of the molecular mechanism behind it was 
obtained by a number of methods, by siRNA-mediated knockdown, exogenous 
overexpression, EMSAs, ChIP, and correlation of expression in human tissue biopsies. CDX-
mediated promoter activation may lead to aberrant esophageal expression of ASBT and 
consequently to an increase in epithelial BA uptake activity by the mucosa in BE. 
Furthermore, my findings may provide an explanation for the correlation between the 
decrease in both ASBT and CDX expression in high-grade esophageal dysplasia. In future 
studies, cooperation and interactions between CDXs and the other known transcriptional 
factors of the ASBT promoter - GATA family, PPARs, VDR, and glucocorticoid receptor - 
would be of interest. 
 
Based on our current preliminary findings, we conclude that CDX1 and CDX2 may also 
regulate the OSTα/β promoters, perhaps with ASBT together in a coordinated manner. This 
regulation may have an important implication in the microenvironment in BE: Upon exposure 
to BAs, ASBT reacts to remove the toxic BAs, OSTα/β on the other side of the membrane is 
upregulated to release the stress of intracellular bile acid load by effluxing them out of the cell. 
EMSAs and ChIPs will be required to confirm the in vitro and in vivo binding of the CDX 
factors to the OST promoters in relevant cell lines. Deletion constructs of the OSTα/β 
promoter will be required to map the exact CDX-responsive regions, which mediate the 
activation. The current ex vivo expression correlation results using human biopsy material 
strongly support the original hypothesis.  
 
There are several limitations to the present study. Despite the progress outlined above, there 
remain important questions that require further study in relation to a more complete 
understanding of transcriptional regulatory mechanisms of the ASBT and OST promoters by 
CDXs. These include: 
CONCLUSIONS AND FUTURE PERSPECTIVES  105     
 
1. The lack of protein-based evidence in siRNA knockdown experiments or CDX 
overexpression experiments with regard to endogenous ASBT expression. This is due 
to the current lack of good CDX1 or CDX2 antibodies available that are suitable for 
western blotting. 
2. I made many attempts to perform immunohistochemical staining of tissue sections 
from paraffin-embedded blocks with anti-ASBT, anti-CDX1, and anti-CDX2 
antibodies, to show co-localization of CDX1 and CDX2 with ASBT in the same cells. 
Although there appeared to be specific nuclear staining with one of the anti-CDX2 
antibodies tested, there were difficulties with anti-CDX1 and anti-ASBT antibodies. 
None of the anti-CDX1 antibodies tested resulted in efficient staining. The ASBT 
antibody produced ambiguous staining, which was at least partly nonspecific. Instead 
of immunohistochemistry, I collected esophageal tissue biopsies from BE patients and 
performed a quantitative correlation analysis of ASBT and CDX mRNA expression. 
There was a significant correlation between CDX and ASBT expression levels in BE 
tissue. Although the mRNA analysis did not absolutely prove co-localization of CDXs 
and ASBT, it strongly supported this hypothesis, and the model of CDXs playing an 
important role in regulating ASBT in BE. 
 
3. I was not able to establish exactly which CDXREs were responsible for the CDX-
mediated ASBT promoter upregulation. Therefore, it is proposed that there is more 
than one CDXRE involved in ASBT promoter activation. 
 
Regarding the protein interaction studies, the candidates to interact with CDXs must be 
validated in further protein-protein interaction assays, for examples, in immunoprecipitation 
or YTH, also to map the exact interacting domains. The validated interacting partners must 
then be functionally tested in promoter-reporter assays by co-transfecting either CDX1 or 
CDX2 with the co-factor candidate with a gene promoter of interests. 
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10 APPENDIX    
Table 1 Sequences of oligonucleotides used for cloning, SDM, EMSAs, and ChIP assays. 
Where applicable, restriction sites introduced are underlined and the corresponding enzymes 
used are given in parentheses. Only the top strands are shown for oligonucleotides used in 
EMSAs. CDXRE consensus motifs are indicated in bold and introduced mutations are in 
italics.  
 
 Sequence (5'-3') 
Cloning oligonucleotides  
hASBT  -99/+525 forward GAGCTCGGAAATTGGATGGAGATCTGGGTC (Sac I) 
hASBT  -99/+525 reverse AAGCTTCTGGCTCTGCTGCTGGTTGAGTT  (Hind III) 
mAsbt -1810/+3 forward GAGGTAAGGTACCAGAGATCAATCAGACCGATG (Kpn I) 
mAsbt -1810/+3 reverse ACAGAAGCACCAGATCTGTCTCTACTGCTAGCTG (Bgl II) 
rAsbt -2975/+147 forward GGTACCAACATTCTTAATCAAAGTCTATATGAG (Kpn I) 
rAsbt -2975/+147 reverse GCTAGCGCAGAAAGTTGCATTTGGG (Nhe I) 
  
SDM oligonucleiotides  
CDXRE_2 GTTGAATACTGAATTAGAATTTGTCCTACAAATTGTG  
CDXRE_3 GGAATATTCAATGTGATTATTACTCTGTGTCCTAACTC  
CDXRE_4 CTGGGTTCTGAACTCCTGAAAACAGGACAATCTCTTC 
CDXRE_8 CCATCTCTGAAGTACTCTGTTACTATGACAACGC  
CDXRE_9 CATATACGTGATGGACACTACAAAGCAATTCC  
CDXRE_10 GGCTCTTGTGATATGGCATGGTTCATTATC  
CDXRE_11 GCCACTGAATGATTAATCGTAACTCTCTGTC  
CDXRE_12 CTAGCGTGATTGTTTGTGATTACTTCCCTAAGGTGGCTTTC  
  
EMSA oligonucleotides  
CDXRE_1_top AGCTTGAATAATAAATTAGAATT 
CDXRE_2_top AGCTATTCAATTTTATTATTACT 
CDXRE_3_top AGCTCTGGGTTATAAACTCCTGA 
CDXRE_4_top AGCTATTTCAATTTATGACTCCAA 
CDXRE_5_top AGCTCATCTATAAAGTACTCTG 
CDXRE_6_top AGCTCATATACTTTATGGACACT 
  
CDXRE_1_top_mut AGCTTGAATACTGAACTTGAATT 
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CDXRE_2_top_mut AGCTATTCAATGTGATTATTACT 
CDXRE_3_top_mut AGCTCTGGGTTCTGAACTCCTGA 
CDXRE_4_top_mut AGCTATTTCAAGTGATGACTCCAA 
CDXRE_5_top_mut AGCTTCCATCTCTGAAGTACTCT 
CDXRE_6_top_mut AGCTCATATACGTGATGGACACT 
CDX_ consensus AGCTAATGATAATTTTATGGATAT 
 
ChIP oligonucleotides  
hASBT_forward  -736 GGGAGTGCTAATCCTACTTAATTTAAGATG  
hASBT_reverse -154 CTGTATCAGTGTTTCCTGGAATTGCTTTGTAG 
hASBT_forward intron 1 CACCTTGGAGTAATCCTTCCAGAAGCCT 
hASBT_reverse intron 1 GAGATCAACAGCAATTATGCAACTCCCTGT 
  
11 DECLARATION 
Experiment Fig 4.3 (F&G) was performed by Moritz Jüttner 
 
 
